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ABSTRACT OF THE DISSERTATION 
 
Paraoxonase 2 (PON2) in Cardiovascular Disease (CVD): The Role of 
PON2 in Acute Myocardial Ischemia-Reperfusion Injury and Diet-Induced 
Obesity 
 
by  
 
Dawoud Sulaiman Abdulmalek  
Doctor of Philosophy in Molecular Toxicology 
University of California, Los Angeles, 2020 
Professor Srinivasa T. Reddy, Chair 
 
 Paraoxonase 2 (PON2) is a ubiquitously expressed antioxidant, anti-
inflammatory protein localized in the inner mitochondrial membrane, where it protects 
against mitochondrial dysfunction and oxidative stress, among other protective 
properties. Human PON2 polymorphisms, particularly human PON2 Ser311Cys, has 
been implicated in the development of coronary artery disease, including myocardial 
infarction and ischemic stroke. Therefore, in this thesis, I explored the cardioprotective 
capacity of PON2 against myocardial infarction, specifically acute myocardial ischemia-
reperfusion injury (IRI). My hypothesis is that PON2 protects against myocardial IRI in 
cardiomyocytes by modulating mitochondrial dysfunction and oxidative stress, 
particularly mitigating mitochondrial lipotoxicity (lipid peroxidation). I employed in vitro 
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(rat ventricular cardiomyocyte cell line, H9c2 cells), ex vivo (cardiomyocytes derived 
from PON2-deficient mice hearts), and in vivo (PON2-deficient mice) models, subjecting 
them to cardiac IRI, to test my hypothesis. I determined that PON2 protects against 
myocardial IRI in cardiomyocytes by reducing mitochondrial dysfunction (stabilizing 
mitochondrial membrane potential and improving calcium retention capacity) and 
oxidative stress (reducing mitochondrial reactive oxygen species) via the reperfusion 
injury salvage kinase pathway (increasing phosphorylated glycogen synthase kinase-
3β). Furthermore, there is an increase in mitochondrial lipid peroxidation in PON2-
deficient mice subjected to myocardial IRI, with an increase in oxidized 
phosphatidylcholine species and eicosanoids (12, 15- hydroxyeicosatetraeonic acid), 
and a decrease in prostanoid production. These injuries are rescued by PON2 
overexpression. Also, I observe an increase in cytoplasmic phospholipase A2 in the 
hearts of PON2-def mice subjected to myocardial IRI, serving as a potential mechanism 
by which PON2 modulates the increase in unesterified eicosanoid production. In order 
to further examine whether PON2 deficiency, exclusively in cardiomyocytes, is sufficient 
to induce increased myocardial IRI, I generated cardiomyocyte-specific PON2-KO mice. 
Lastly, I investigated the protective role of a novel drug, HSG4112, against 
cardiovascular risk factor, diet-induced obesity. I found that HSG4112 protects against 
diet-induced obesity by enhancing lactonase/arylesterase activity, reducing body weight 
and fat mass, and increasing lean (muscle) mass. Nevertheless, the protective effects 
of HSG4112 are significantly reduced in PON2-def mice, suggesting that PON2 is at 
least partly involved as a mode of action for HSG4112’s protective capacity.  
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Chapter 1: Introduction 
Abbreviations:  
CVD Cardiovascular Disease 
PON Paraoxonase  
WT Wild-type 
PON2-def PON2-deficient  
LDLR-KO Low density lipoprotein receptor knock-out 
WD Western diet 
HF/HS High fat/high sucrose 
CL   Cardiolipin 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
ROS Reactive oxygen species 
HETE 5-Hydroxyeicosatetraenoic acid 
POVPC 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine 
PGPC 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 
cPLA2 Cytoplasmic phospholipase A2 
IRI Ischemia-reperfusion injury 
ROS Reactive oxygen species 
mPTP Mitochondrial permeability transition pore 
Akt Protein kinase B 
IMM Inner mitochondrial membrane 
SNP Single nucleotide polymorphism 
 
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide, including the United States.1-3 In the United States, CVD deaths surpass that 
of cancer and chronic lung disease combined, with one person dying from CVD every 
37 seconds, with deaths from heart disease accounting for about one in four deaths.1-3 
CVD includes an array of diseases associated the entire vasculature, including stroke, 
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heart failure, high blood pressure, and coronary heart diseases (CHD), which includes 
coronary artery diseases (CAD) like atherosclerosis. Subsequently, CAD can lead to 
CHD manifesting as ischemia and myocardial infarction (MI). Moreover, CHD is the 
leading cause of CVD deaths (43.2%) in the United States, with an American 
experiencing a MI every 40 seconds.1 Additionally, diet-induced obesity in adults is one 
of the leading risk factors (~40%) for many individuals suffering from CVD/CHD or are at 
a higher risk for developing CVD.1 The financial impact of CVD is tremendous, with an 
estimated $351.2 billion in direct and indirect costs.1 In 2016, The American Heart 
Association estimated that by 2035, the direct and indirect costs of CVD will reach $1.1 
trillion.1  
There is a lack of therapeutic agents to treat MI and diet-induced obesity. Therefore, 
discovery of novel molecules and mechanisms that protect against the debilitating 
outcomes of MI, specifically ischemia-reperfusion injury (IRI) and diet-induced obesity 
are of vital importance, particularly for the development of therapeutic targets. An 
underlying feature of both diseases is oxidative stress and mitochondrial dysfunction.4 
Therefore, studying a therapeutic target that can modulate these pathologies is critical. 
Paraoxonase 2 (PON2), a ubiquitously expressed anti-oxidant and anti-inflammatory 
protein located in the mitochondria, has been shown to be protective against 
atherosclerosis, obesity and heart failure.5-7 Moreover, the human PON2 Ser311Cys 
(S311C) polymorphism, a fairly common SNP, has been linked to coronary artery 
disease, including myocardial infarction and ischemic stroke.8-13 Consequently, the 
primary aim of my thesis will be to examine the role of PON2 against myocardial IRI, 
particularly in cardiomyocytes. In addition, I will examine the potential role of PON2 in 
3 
 
modulating the protective effects of a novel therapeutic, HSG4112, in mitigating diet-
induced obesity, one of the largest risk factors associated with CHD.   
The mitochondria are intimately involved in the pathogenesis of myocardial IRI, 
which is characterized by the ischemic injury, or occlusion of a coronary artery 
(myocardial infarction), and the subsequent reperfusion injury upon restoration of blood 
flow to the myocardium via primary percutaneous coronary intervention (PPCI).14 A 
primary outcome of ischemia is the switch from aerobic to anaerobic respiration, 
resulting in the depletion of ATP.15  A key consequence is the inhibition of crucial ATP-
dependent ion channels that result in the accumulation of sodium and, more critically, 
calcium. Furthermore, oxygen, an electron acceptor in the electron transport chain, is 
absent, resulting in a large build-up of electrons within the mitochondrial membranes.16 
These ischemic injuries prime the cell for a further injury upon reperfusion. The 
reintroduction of oxygen during reperfusion interacts with the free electrons in the 
mitochondrial membrane, resulting in the formation of reactive oxygen species (ROS), 
specifically superoxides.17 The influx of ROS, coupled with the unresolved calcium 
overload, trigger the opening of mitochondrial permeability transition pore (mPTP). 15, 16 
mPTP is a nonselective channel of the inner mitochondrial membrane (IMM) and its 
opening results in mitochondrial membrane depolarization, uncoupling of oxidative 
phosphorylation, release of ROS and cytochrome c to the cytosol, inducing pro-
apoptotic, caspase signaling cascade ultimately leading to the death of 
cardiomyocytes.15, 16, 18, 19 Nevertheless, despite the seemingly paradoxical reperfusion 
injury, quick and timely PPCI upon the onset of the ischemia results in a critically 
significant salvaging of the myocardium that would otherwise be lost if the ischemic 
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injury is allowed to persist.14 Consequently, discovering novel genetic targets and 
pharmacological interventions that aim to mitigate reperfusion injury, i.e. by reducing 
ROS generation or mPTP opening, prior/during PPCI are instrumental in the fight 
against myocardial IRI. Yet, many therapies have been largely unsuccessful.20, 21  
During IRI, a fraction of glycogen synthase kinase-3β (GSK-3β), a ubiquitously 
expressed serine/threonine kinase, is localized to the sarcoplasmic 
reticulum/endoplasmic reticulum (SR/ER) and the mitochondria-associated ER 
membranes (MAMs) in the heart.22  In addition, the inhibition, via phosphorylation, of 
GSK-3β inhibits the opening of mPTP and is regulated by the reperfusion injury salvage 
kinases (RISK), including phosphatidylinositol 3-kinase (PI3K) and Akt.23-25 Therefore, 
discovering a molecule that modulates the phosphorylation of GSK-3β will serve as a 
potential therapeutic target of IRI. 
Mitochondrial membrane lipids, especially within the IMM like CL, play various roles 
within the mitochondria including protein biogenesis, energy production, membrane 
function, and apoptosis.26 The major phospholipids in the mitochondrial membranes are 
PC, PE, and CL, which make-up ~40%, 30%, and 15% of the total lipids respectively.26 
These mitochondrial membrane lipids are susceptible to oxidative damage during IRI, 
which leads to lipid peroxidation of the phospholipids and their esterified 
polyunsaturated fatty acid tails, like linoleic and arachidonic acid, which can be further 
oxidized to pro-inflammatory eicosanoids and prostanoids.27-34 Furthermore, this 
mitochondrial lipid peroxidation causes the loss of IMM organization, decreases in CL 
content, increases in CL peroxidation and increases the permeability of the plasma 
membrane that lead to increases the release of cytochrome c into the cytosol and 
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disruption of membrane potential.27, 28, 35-38 Consequently, lipid peroxidation and or their 
secondary, endogenous toxic products also have the potential to be promising 
therapeutic targets against IRI.  
PON2 is part of a gene family consisting of three members, PON1, PON2, and 
PON3, which are located adjacent to each other on the long arm of chromosome 7 in 
humans and chromosome 6 in mice.4, 39 Although PON1 was discovered first, PON2 is 
the oldest member of the gene family, which gave rise to PON1 and PON3 by gene 
duplication. All three genes are highly conserved in mammals and exhibit great 
homology with each other, sharing approximately 60% at the amino acid level and about 
70% at the nucleic acid level. 40 PON1 and PON3 are mainly expressed in the liver and 
associate with High Density Lipoproteins (HDL) in the circulation (PON3 on a much 
smaller scale), while PON2 is ubiquitously expressed as an intracellular protein in nearly 
all tissue types.41 PON1 was initially discovered as an enzyme with the ability to 
hydrolyze organophosphates like chlorpyrifos oxon, dizoxon, and paraxon, the active 
metabolite of insecticide parathion.4, 41 Nevertheless, all three PONs exhibit lactonase 
activity, in which they can hydrolyze a variety of lactones, namely acyl- homoserine 
lactones (AHLs) that mediate bacterial quorum-sensing (QS) signals. More specifically, 
PON2 is responsible for attenuating the biological effects of the Pseudomonas 
aeruginosa QS molecule N-(3-oxo-dodecanoyl)-L-homoserine lactone (3OC12) by 
decreasing its availability for receptor-mediated effects as well as promoting calcium 
release and stress signaling via intracellular acidification.42 Recently, Li et al. generated 
soluble human PON2 that has shown promise as a novel therapeutic approach for 
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reducing antibiotic resistance and fighting chronic infections through the enzymatic 
inactivation of QS signaling molecules, like AHLs.43 
PON2 has been shown to have various anti-oxidant and anti-inflammatory 
properties, is protective against a range of diseases including bacterial infection, cancer, 
and cardiovascular disease.4, 5, 44-46 However, the physiological substrates and 
molecular mechanisms through which the PON enzymes exhibit these anti-oxidant and 
anti-inflammatory properties remain generally unknown. PON2 is a ~43 kDa protein 
localized within the mitochondria, specifically associating with complex III of the IMM.5 A 
PON2-deficient mouse model was developed by our lab to test the role of PON2 in 
various disease models.44 PON2 deficiency alters mitochondrial function by decreasing 
mitochondrial complex I and III activity and total ATP levels and alters mitochondrial 
oxidative stress by increasing mitochondrial superoxide production, increasing lipid 
peroxidation and decreasing reduced glutathione levels.5, 45 Additionally, PON2 
deficiency aggravated the development of atherosclerosis.5, 47 Moreover, PON2 is 
associated with endoplasmic reticulum (ER) and its expression is induced in response 
ER stress pathway unfolded protein response (UPR), which reduces intracellular ROS 
and UPR-associated oxidative stress and caspase induced cell death by regulation of 
calcium homeostasis.46, 48 Within the IMM, PON2 attenuated CL peroxidation, 
cytochrome c release and caspase activation.49 Therefore, given that the 
pathophysiology of myocardial IRI largely converges onto the mitochondria and 
the well-established protective capacity of PON2 against mitochondrial 
dysfunction and oxidative stress, I hypothesize that PON2 is protective against 
7 
 
myocardial IRI by mitigating mitochondrial dysfunction, oxidative stress, and lipid 
peroxidation.  
Recently, I have reported the critical protective role that PON2 plays in modulating 
myocardial Ischemia-Reperfusion Injury, which I further discuss in chapter 2.50 In brief, 
our study demonstrates that PON2 expression is inversely related to IRI severity as 
PON2-def mice subjected to IRI exhibited a significant increase in infarct size when 
compared to WT controls. Since mitochondrial dysfunction and oxidative stress are 
hallmark consequences of myocardial IRI, we tested the mitochondrial integrity of 
PON2-def mice following IRI. Our findings reveal that PON2-def mice have an inherent 
mitochondrial defect that, when in the presence of an exogenous stressor (i.e. 
extramitochondrial calcium), manifests into basal mitochondrial dysfunction. 
Furthermore, mitochondria isolated from PON2-def mice subjected to IRI had a 
significant reduction in calcium retention capacity (CRC) and oxidative stress, when 
compared to WT controls. We further examined and validated these results specifically 
within mitochondria from the cardiomyocyte subpopulation. In addition, PON2 
modulates mitochondrial membrane potential, an essential consequence of 
mitochondrial dysfunction, driven in part by mPTP opening. These observations 
demonstrate a clear role for PON2 in protection against myocardial IRI as lack of PON2 
results in increased IRI, in the form of mitochondrial dysfunction and oxidative stress, 
specifically within the cardiomyocyte subpopulation.  
In chapter 3, I investigate the role novel role that PON2 plays in modulating 
mitochondrial phospholipid composition and lipid peroxidation, specifically evaluating 
eicosanoid and prostanoid production. In brief, PON2 deficiency significantly modulates 
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mitochondrial membrane phospholipid composition by reducing PC and increasing PE 
species under baseline conditions, which largely held true post-IRI. Many of significantly 
altered mitochondrial phospholipids contain esterified linoleic acid (18:2) and 
arachidonic acid (20:4), which serve as substrates for oxidation (enzymatic or non-
enzymatic) into various eicosanoids and prostanoids.51 In fact, I observe that there is a 
significant increase in both eicosanoid and prostanoid production as well as PC 
oxidation (POVPC and PGPC) in the mitochondria of hearts from PON2-def mice under 
baseline and post-IRI conditions. Furthermore, PON2 overexpression rescues this 
phenotype, supporting its protective capacity. Lastly, cytoplasmic phospholipase 2 is 
upregulated in PON2 deficient hearts subjected to IRI, serving as a potential molecular 
mechanism for PON2’s capacity to modulate mitochondrial lipid composition and 
peroxidation.  
Consequently, I set out to determine if PON2 deficiency specifically within 
cardiomyocytes is sufficient to inducing the increase in myocardial IRI that I observed in 
my global PON2 knockout (PON2-def) mouse model.50 Therefore, I generated two novel 
cardiomyocyte specific PON2-KO transgenic mouse models to explore this hypothesis, 
using both CRISPR-Cas9 and FLP/Cre recombinase systems, which I outline in chapter 
3.  
Lastly, in chapter 5, I explore the capacity of novel drug, HSG4112, to protect 
against the CVD risk factor, diet-induced obesity, and the potential role of PON2 as a 
mode of action for its protective properties. In brief, HSG4112 enhances lactonase and 
arylesterase activity and induces PON1 and PON3 protein expression in WT, PON1-KO 
and PON2-KO mice under baseline, chow fed conditions. HSG4112’s protective effects 
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are partly reduced with PON2 deficiency. This is observed in preserved capacity of 
HSG4112 to reduce body weight in both WT and PON2-def mice, while losing its 
potential to reduce fat mass, increase muscle mass, enhance lactonase activity, and 
decrease plasma glucose levels. Nevertheless, HSG4112 was able to significantly 
reduce the body weight and fat mass, increase muscle mass, and decrease plasma 
glucose levels in hyperlipidemic mice fed a western diet.  
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Chapter 2: Paraoxonase 2 protects against acute myocardial Ischemia-
reperfusion injury by modulating mitochondrial function and oxidative stress via 
the PI3K/Akt/GSK-3β RISK pathway 
Abbreviations:  
AMI Acute myocardial infarction 
CM Cardiomyocytes 
IRI Ischemia-reperfusion injury 
LAD Left anterior descending 
ROS Reactive oxygen species 
mPTP Mitochondrial permeability transition pore 
RISK Reperfusion injury salvage kinase 
PI3K Phosphoinositide 3-kinase 
Akt Protein kinase B 
WT Wild-type 
PON2-def PON2 deficient  
CM Cardiomyocyte 
IMM Inner mitochondrial membrane 
OMM Outer mitochondrial membrane 
CRC Calcium retention capacity 
GSK-3β Glycogen synthase kinase 3β 
MAMs Mitochondria-associate ER membranes 
 
2.1 Introduction 
Acute myocardial infarction (AMI) is one of the leading causes of morbidity and 
mortality worldwide.14, 52 AMI is characterized by blocked blood flow to the coronary 
arteries, resulting in various biochemical and metabolic alterations within the 
myocardium, including mitochondrial dysfunction and, if prolonged, the death of 
cardiomyocytes (CM). Surgical interventions, like stents, are critical in mitigating the 
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damage to the myocardium by reperfusing, or restoring blood flow to the heart; 
however, AMI induced ischemic injury primes the cells for further injury once reperfusion 
occurs.14, 15  
Mitochondria are intimately involved in the pathogenesis of myocardial ischemia-
reperfusion injury (IRI). A primary outcome of AMI induced ischemic injury is the switch 
from aerobic to anaerobic respiration, resulting in the depletion of ATP.15  A key 
consequence is the inhibition of crucial ATP-dependent ion channels that result in the 
accumulation of sodium and calcium. In addition, oxygen, an electron acceptor in the 
electron transport chain, is absent during ischemia, resulting in a large build-up of 
electrons within the mitochondrial membranes.16 Upon reperfusion, the restoration of 
oxygen results in the formation of ROS, specifically superoxides.17 The calcium 
overload and ROS generation converge onto the mitochondria and trigger the opening 
of the mitochondrial permeability transition pore (mPTP) during reperfusion injury 
resulting in cell death.16 The reperfusion injury salvage kinases (RISK) pathway, 
PI3K/Akt/GSK-3β, has been shown to be cardioprotective against IRI by 
phosphorylating glycogen synthase kinase-3β (GSK-3β), a ubiquitously expressed 
serine/threonine kinase, which inhibits the opening of the mPTP.23-25 There are many 
therapies currently attempting to mitigate myocardial IRI by targeting mPTP opening or 
the RISK pathway, but have largely been unsuccessful.14, 21 These therapies only target 
one aspect of a highly complex disease. Consequently, the need to find a novel 
therapeutic agent that has a multifaceted connection with myocardial IRI pathogenesis 
is critical.  
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PON2 is part of a gene family consisting of three members, PON1, PON2, and 
PON3, which are located adjacent to each other on the long arm of chromosome 7 in 
humans and chromosome 6 in mice.4  PON2 polymorphisms, particularly PON2 
Ser311Cys, have been associated with increased risk of coronary heart disease and 
ischemic stroke in various human populations.9, 10, 12, 13, 53-56  PON2 has been shown to 
have various anti-oxidant and anti-inflammatory properties.4, 5, 44-46 PON2 deficiency 
alters mitochondrial function by decreasing mitochondrial complex I and III activity and 
total ATP levels and alters mitochondrial oxidative stress by increasing mitochondrial 
superoxide production, increasing lipid peroxidation and decreasing reduced glutathione 
levels.5, 45 Additionally, PON2 deficiency aggravated the development of 
atherosclerosis.5, 47 PON2 is localized within the mitochondria, specifically associating 
with complex III of the IMM.5 Furthermore, PON2 attenuates cardiolipin peroxidation, 
cytochrome c release and caspase activation.49  
The role of PON2 against acute IRI has not been investigated to date. Many of 
the injuries resulting from IRI converge on the mitochondria, making it a fundamental 
organelle to study in this disease model. Since PON2 and its antioxidant activity are 
localized to the mitochondria, we hypothesized that PON2 plays a protective role 
against acute myocardial IRI by modulating mitochondrial function and oxidative stress. 
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2.2 Materials and Methods 
2.2.1 Experimental Animals 
C57BL/6J, wild-type (WT) mice and PON2 deficient (PON2-def) male mice 8-10 
weeks of age were used for the in vivo studies. The wild type controls used for all our 
studies were derived from PON2 heterozygous intercrosses. All animal studies were 
approved by the IACUC and Animal Research Committee (ARC) at UCLA, and 
designed to prevent/reduce any stress/pain. 
2.2.2 H9c2 Cell Culture Methods 
H9c2(2-1) (ATCC CRL-1446), a rat ventricular cardiomyocyte cell-line, was 
utilized for the in vitro studies. ATCC-formulated DMEM (catalog#30-2002, ATCC) was 
used to culture the cells, with the addition of 10% FBS (Catalog#26140079, 
ThermoFisher) and 1% Penicillin-Streptomycin (catalog#15140122, ThermoFisher) for 
complete growth medium. H9c2 cells were transfected with pcDNA3.1+ plasmid 
expressing human PON2 (H9c2-hPON2) or empty vector (H9c2-EV) (Catalog#V790-20, 
Addgene) using Lipofectamine 2000 transfection reagent (catalog#11668027, 
ThermoFisher). Stable cell-lines were generated by selection of positive colonies via 
neomycin selection (Geneticin, catalog#10131035, ThermoFisher).  
2.2.3 Ischemia-Reperfusion Injury 
In vivo IRI- Left Anterior Descending (LAD) Coronary Artery Occlusion: Mice were 
subjected to vivo IRI as previously described.57 In brief, mice were anesthetized with 
ketamine (100 mg/kg i.p.) and xylazine (10 mg/kg i.p.). After general anesthesia, the 
baseline ECG and ECHO were performed. Under mechanical ventilation, the chest was 
opened and the heart exposed. A suture was placed around the left anterior descending 
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coronary artery (LAD) three quarters of the distance from the base to the apex, and 
tightened to occlude the LAD permanently for 30 minutes, which was confirmed by ST 
elevation in ECG. The ligature was released to start reperfusion. The chest was then 
closed and the mice were allowed to recover. Twenty-four hours later, Evans Blue dye 
was injected through the right ventricle to assess area at risk, and mice 
were euthanized using approved procedures and the hearts removed. 2 mm thick 
sections of the ventricles were then incubated in 1% triphenyltetrazolium chloride (TTC) 
at 37oC for 15 minutes to assess infarct size.  
Ex vivo IRI- Mouse hearts were subjected to ex vivo IR via the Langendorff Apparatus 
as previously described.57 In brief, mice were anesthetized with an intraperitoneal 
injection of pentobarbital sodium (50 mg/kg). Heparin (200 IU/kg) was also administered 
to prevent blood coagulation. Once anesthetized, the heart was quickly (within 60 
seconds) removed, mounted, and perfused through the ascending aorta in a 
Langendorff apparatus with Krebs Henseleit bicarbonate buffer (KH Buffer) (mM): 
glucose 11.1, NaCl 118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25.0, CaCl2 2 at pH 
7.4 bubbled with 95% O2/5% CO2 at 37 °C. Following a 10 minute stabilization period, a 
global normothermic (37oC) ischemic episode was induced by stopping perfusate for 20 
minutes followed by a 5-minute reperfusion of the heart with KH. CM were immediately 
isolated post-reperfusion (refer to Cardiomyocyte Isolation). 
In vitro IRI- Hypoxia-Reoxygenation via Hypoxia Chamber: To induce hypoxia in cells, 
cell media was changed from normal, growth media (refer to H9c2 Cell Culture 
Methods) to a low nutrient DMEM (Life Technologies, Catalog# 11966-025) without 
growth factors and were placed into a hypoxic plastic chamber under hypoxic gas 
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conditions (≤2% O2, 5% CO2, nitrogen balanced) at 37oC for 3 hours. Hypoxia was 
confirmed by HIF-1α upregulation (data not shown). The cells were then reoxygenated 
by replacing the media back to regular growth media and placing the cells back to 
normoxic gas conditions (~20-21% O2 and 5% CO2) at 37oC for 2 hours. The cells were 
then used for all downstream assays.  
2.2.4 Mitochondrial Isolation and Protein Quantification 
Mitochondria were isolated from whole hearts of PON2-def and WT, C57Bl/6J, 
mice, as previously described.24, 57, 58 In brief, the heart were finely minced with scissors 
and homogenized in buffer A (containing in mM: 70 sucrose, 210 mannitol, 1 EDTA, 50 
Tris-HCl, pH 7.4 at 4oC) and centrifuged at 1,300 g for 3 minutes. The supernatant was 
filtered through cheesecloth and centrifuged at 10,000g for 10 minutes; the pellet was 
then resuspended in in buffer C (containing in mM: 150 sucrose, 50 KCl, 2 KH2PO4, 5 
succinic acid, and 20 Tris-HCl, pH7.4 at 4oC); protein concentration was measured by 
Bradford Assay. 
2.2.5 Cardiomyocyte Isolation 
CM were isolated as previously described.59, 60 In brief, mice were anesthetized 
with an intraperitoneal injection of pentobarbital sodium (50 mg/kg). Heparin (200 IU/kg) 
was also administered to prevent blood coagulation. The heart was quickly (within 60 
seconds) removed and mounted on a modified Langendorff apparatus and secured by 
the ascending aorta. The heart was then perfused with Tyrode’s solution [130 mM NaCl, 
5.4 mM KCL, 0.6 mM NaH2PO4*H20, 1 mM MgCl2*6H20, 10 mM HEPES, 10 mM 
Glucose, 5 mM Taurine; oxygenated with 95% O2, 5% CO2; at pH 7.4] at 37oC for 5 
minutes. The heart is then perfused for 5-6 minutes at 37oC with Tyrode’s solution 
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containing 0.5 U/mL Protease Type-XIV (Sigma, catalog# P5147) and 140.5 U/mL 
Collagenase Type-2 (Worthington Biochemicals, catalog# LS004176). Lastly, the heart 
was perfused for 5 minutes at 37oC with KB solution [25 mM KCL, 10 mM KH2PO4, 2 
mMMgSO4*7H20, 5 mM HEPES, 20 mM Glucose, 20 mM Taurine, 5 mM Creatine, 100 
mM K-Glutamate, 10 mM Aspartic Acid, 5 mM EGTA, and 0.10% BSA (fatty acid free); 
oxygenated with 95% O2, 5% CO2; at pH 7.4]. The atria were removed and the 
ventricles were minced in KB solution to dissociate the cells. The CM were then filtered 
through a 100 µm strainer and centrifuged for 5 minutes at 1000xg. The CM were then 
ready for downstream use.  
2.2.6 Calcium Retention Capacity 
The calcium retention capacity (CRC) assay was performed to determine the 
threshold for mPTP opening in response to calcium overload.25, 57, 58 In brief, 0.5 µM 
calcium green-5N was used to determine free calcium concentration outside the 
mitochondria using excitation and emission wavelengths set at 500 and 530 nm, 
respectively. 
In vivo IRI: 500µg protein of isolated mitochondria from the whole heart of the mice was 
resuspended in 2mL buffer C (containing in mM: 150 sucrose, 50 KCl, 2 KH2PO4, 5 
succinic acid, and 20 Tris-HCl, pH7.4 at 4oC); CaCl2 pulses (20 nmoles) were added 
every minute until a sustained calcium increase is established, indicating mPTP 
opening. The results were measured as nmoles of calcium per milligram of 
mitochondrial protein.  
Ex vivo IRI and in vitro HRI: CM and H9c2 cells are resuspended in 2mL buffer C and 
permeabilized with an optimized concentration of 25 µM and 3 µM digitonin, 
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respectively. CaCl2 pulses (16 nmoles) were added every minute until a sustained 
calcium increase is established, indicating mPTP opening. The results were measured 
as nmoles of calcium per 5.0x104 cells (CM) and 1.5x106 cells (H9c2 cells).  
2.2.7 Reactive Oxygen Species (ROS) Production  
Mitochondrial ROS production was assessed.  
In vivo IRI: In brief, mitochondria (100µg) were resuspended in 50µL reaction buffer 
(containing in mM: 125 KCl, 10 HEPES, 5 MgCl2, 2 K2HPO4, pH 7.4 at 4oC) to 
determine complex I or complex II driven H2O2 production; mitochondrial H2O2 
production was assessed by using horseradish peroxidase (2 units/mL) H2O2-
dependent oxidation of nonfluorescent Amplex Ultra Red (50µM) to fluorescent resorufin 
red, at an excitation wavelength of 545 nm and an emission wavelength of 590 nm for 
20 minutes.61 The results were measured as nmoles of H2O2 divided by minutes per 
microgram of mitochondrial protein, but expressed as fold change.  
Ex vivo IRI and in vitro HRI: MitoSox Red mitochondrial superoxide indicator (Molecular 
Probes, catalog# M36008) was utilized and the assay was run based on manufacturer 
recommendations. In brief, an optimized 5 µM concentration of MitoSox Red was 
determined to be the most effective concentration. In brief, CM and H9c2 cells were 
plated and subjected to IRI or HRI, respectively. The cells were washed with PBS. 
Then, the cells were incubated with unsupplemented media containing a concentration 
of 5 µM MitoSox Red for 45 minutes. Afterward, the cells were washed 3 times with 
PBS. The cells were then pelleted (5 minute spin at 1000xg) and resuspended with 300 
µL of PBS in placed plastic culture tubes (Fisher, catalog# 14-961-10A). Mitochondrial 
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superoxide levels were then determined in the live cells via flow cytometry using an 
absorption/emission maxima of ~510/580 nm. The data is expressed as fold change.  
2.2.8 Quantitative RT-PCR Analysis 
Total RNA was isolated from whole hearts of PON2-def and WT mice post in vivo 
IRI by RNeasy mini kit (Qiagen, USA). 1 microgram of RNA was used to generate cDNA 
via reverse transcription with a High-Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Life Technologies, ThermoFisher, USA). The qPCR reaction mixture 
consisted of 2 microliters of cDNA, gene specific primers and iQ SYBR Green Supermix 
(Bio-Rad, Hercules, CA, USA) and was run in a MyiQ Single-Color Real-Time PCR 
Detection System (Bio-Rad, Hercules, CA, USA). mRNA gene expression levels were 
quantified and normalized to mouse GAPDH levels. The primer pairs are as follows: 
mouse PON2 (forward) 5’-GAGTCAGCTGGGGCTTTGACTTGGC-3’ and (reverse) 5’-
ATTGGTGGCGTAGAAGTGGGTGGGC-3’, mouse GAPDH (forward) 
5’TTGTCATGGATGGACCTTGGCCAGG-3’ and (reverse) 5’-
TGCCATTTGCAGTGGCAAAGTGG-3’. 
2.2.9 Immunoblotting 
50 micrograms of protein from whole heart lysates (PON2-def and WT) or H9c2 
cells were loaded on 4-20% Mini-PROTEAN TGX Stain-Free protein gels (Bio-Rad, 
Hercules, CA, USA) and transferred to nitrocellulose membranes. The membranes were 
blocked for 1 hour at room temperature in Tris-buffered Saline with 0.1% Tween 20 
(TBST) containing 5% (w/v) BSA. The following primary antibodies were used at the 
specified dilutions: human PON2 (R&D Systems, Biotechne brand, USA) at 1:1000, 
GSK-3β (27C10) (Cell Signaling Technology, USA) at 1:1000, pGSK-3β (ser9) (Cell 
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Signaling Technology, USA) at 1:1000, CHOP (Cell Signaling Technology, USA) at 
1:750, GAPDH (ab9485) (Abcam, USA) at 1:10,000. Primary antibodies were diluted in 
TBST containing 5% BSA at 4oC overnight, followed by incubation with appropriate 
secondary antibody (1:5000 dilution) coupled to HRP for 1 hour. Protein was detected 
using Immobilon Western Chemiluminescent HRP Substrate (Millipore Sigma, USA).  
2.2.10 Cell Apoptosis Assessment  
Cell apoptosis was determined in CM (6x104 cells) isolated from WT and PON2-
def mice hearts by evaluating caspase-3/7 activity using the CellEvent Caspase-3/7 
Green Detection Reagent (catalog#C10423, ThermoFisher) via live cell fluorescence-
imaging as described by manufacturer’s protocol.   
2.2.11 ATP Quantification 
ATP levels were quantified as previously described.5 In brief, ATP levels from CM 
(6x104 cells) isolated from WT and PON2-def mice hearts were evaluated as described 
by the manufacturer’s protocol (Bioassay System).  
2.2.12 Statistical Analysis 
Student’s t-tests were carried out between all studies with two groups. Data from 
experiments with more than 2 or more groups were compared using a one-way ANOVA 
model. After a significant overall group effect was established, Tukey’s pairwise 
comparisons were carried out to determine specific group to group differences. 
Experiments were repeated 2-3 times to ensure that the results were consistent and 
reproducible. All data is represented as mean±SEM. A p-value less than 0.05 was 
considered statistically significant.  
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2.3 Results 
2.3.1 PON2 expression is associated with reduced infarct size following myocardial IRI 
We confirmed PON2 protein expression in both neonatal and adult WT mice 
(Figure 1A). When WT mice were subjected to in vivo IRI (Figure 1B), PON2 gene 
expression levels were approximately 2-fold higher in hearts from the IRI mice when 
compared to the sham group (n=5/group) (Figure 1C). IRI-induced PON2 gene 
expression further supported our hypothesis that PON2 may play a role in modulating 
IRI. To further explore the role of PON2 in myocardial IRI, we used a PON2 deficient 
(PON2-def) mouse line previously generated in our lab.5, 44, 47 Echocardiograms were 
performed on both WT and PON2-def mice under baseline (untreated) conditions to 
assess heart function and structure, and no significant differences were found 
(Supplemental Figure 1 and 2). Following in vivo IR, we observed that PON2-def mice 
had roughly 2-fold larger infarct size compared to controls (n=8/group, Figure 1D), 
quantified as the percentage of the infarct size over the area at risk (IS/AAR) and infarct 
size over left ventricle area (IS/LV) (Figure 1E).  
2.3.2 PON2 deficiency leads to cardiac mitochondrial dysfunction and decreased pGSK-
3β levels following myocardial IRI  
To determine the role of PON2 in modulating mitochondrial dysfunction and 
oxidative stress against myocardial IRI, we isolated cardiac mitochondria from PON2-
def mice and WT controls subjected to in vivo IRI and measured the threshold for mPTP 
opening in response to exogenous calcium overload using the calcium retention 
capacity (CRC) assay. Mitochondria from the PON2-def mice had significantly lower 
CRC than WT mice in both baseline (untreated) [274.3±15.39 in WT, 214.9±13.46 in 
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PON2-def, nmoles Ca2+/mg mitochondrial protein; n=7/group; p<0.05] and IR conditions 
[250±41 in WT, 173±19 in PON2-def, nmoles Ca2+/mg mitochondrial protein; n=6/group; 
p<0.05] (Figure 2A and 2B). Additionally, mitochondrial ROS production was 
approximately 2-fold greater (p<0.05) in the PON2-def mice (n=4) versus WT controls 
(n=5) following IRI (Figure 2C and 2D), and PON2-def hearts had significantly higher 
protein expression (p<0.05) of endoplasmic reticulum (ER) stress marker, CHOP, 
versus WT mice (Figure 2E and 2F), suggesting a potential role that PON2 can be 
playing in modulating ER stress and calcium release in response to IRI. PON2-def 
hearts also had significantly lower levels of phosphorylated, cardioprotective GSK-3β, 
the downstream effector in the RISK pathway, compared to WT controls (p<0.05), 
Figure 2H). Taken together, the mitochondria from PON2-def mice exposed to IRI are 
more dysfunctional, having a reduced calcium retention capacity, increased ROS 
production, increased ER stress, and decreased pGSK-3β levels when compared to WT 
controls.  
2.3.3 Cardiomyocytes deficient in PON2 exhibit increased mitochondrial dysfunction, 
oxidative stress, and apoptosis following IRI  
While the above studies identified the protective effect of PON2 against IRI in 
whole heart tissue, we sought to investigate the role of PON2 specifically within CM. 
Hearts from PON2-def and WT mice were subjected to ex vivo IRI via the Langendorff 
apparatus, with a 20-minute ischemic episode, followed by a 5-minute reperfusion 
(Figure 3A). CM were isolated from the ventricles of IRI hearts and evaluated for ATP 
levels, CRC, ROS production and cell apoptosis. CM from PON2-def IRI hearts 
exhibited a significant decrease in ATP levels versus WT CM controls (p<0.05), with no 
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change in baseline conditions (Figure 3B). CM from PON2-def, non-IR injured hearts 
showed a baseline decrease in CRC versus WT control CM [267 in WT CM, 123 in 
PON2-def CM nmoles of Ca2+ per 5.0x104 cells; n=3/group; p<0.05] (Figure 3C). This 
data supports an inherent mitochondrial defect in PON2-def mice when handling 
extramitochondrial calcium (Figure 2B). Furthermore, CM isolated from PON2-def IR 
injured hearts have further reduction in CRC when compared to CMs from WT IRI 
hearts [176 in WT CM (IRI), 80 in PON-2-def CM (IRI), nmoles of Ca2+ per 5.0x104 cells; 
n=3/group; p<0.01] (Figure 3D). In addition, ROS production, particularly mitochondrial 
superoxide levels, was significantly increased (p<0.01) in CM from PON2-def hearts 
subjected to IRI versus CM controls, with no change in the baseline conditions (Figure 
3E). Lastly, we observed a significant increase in cell apoptosis in the CM from PON2-
def hearts subjected to IRI compared to WT controls as assessed by caspase-3/7 
activity (p<0.01), with no significant baseline differences between the groups (Figure 
3F).  
2.3.4 Overexpression of human PON2 in H9c2 cells results in increased pGSK-3β 
following hypoxia-reoxygenation injury 
To investigate the molecular mechanism and a potential therapeutic role for 
PON2 protection against IRI, we stably overexpressed human PON2 in the rat 
ventricular cardiomyocyte cell-line, H9c2, and subjected them to hypoxia-reoxygenation 
injury (HRI) (Figure 4A/B). We found a significant decrease in CHOP protein levels in 
the PON2 overexpression cells (H9c2-hPON2) versus the empty vector controls (H9c2-
EV) as determined by western blot (Figure 4C/D). In addition, we found a significant 
increase in the pGSK-3β/GSK-3β ratio in the H9c2-hPON2 cells versus H9c2-EV 
23 
 
controls (Figure 4F). No differences in pGSK-3β/GSK-3β levels were observed under 
baseline (untreated) conditions (Supplemental Figure 3).   
2.3.5 Overexpression of PON2 rescues IRI via activation of the PI3K/Akt/GSK-3β 
Pathway  
To further elucidate the cardioprotective role that PON2 overexpression could 
play during IRI and the potential contribution of the RISK pathway, we subjected H9c2-
hPON2 cells and H9c2-EV controls to HRI with and without LY294002, a potent PI3K 
inhibitor, and assessed mitochondrial CRC, ROS production (superoxide levels), and 
cell apoptosis. H9c2-hPON2 cells subjected to HRI exhibited increased CRC compared 
to H9c2-EV cells [141.7±16.67 in H9c2-EV, 200±14.43 in H9c2-hPON2, nmoles of Ca2+ 
per 1.5x106 cells, p<0.05] (Figure 5B), indicating that PON2 overexpression increases 
the threshold for the opening of the mPTP in response to calcium overload. In addition, 
H9c2-hPON2 cells demonstrated a 40% reduction (p<0.01) in ROS generation versus 
the H9c2-EV control cells post HRI (Figure 5D). Following HRI, H9c2-hPON2 cells were 
markedly resistant to apoptosis when compared to H9c2-EV controls [5% TUNEL 
Positive cells in H9c2-hPON2 cells versus 34% in H9c2-EV cells, p<0.0001] (Figure 5F); 
however, the protective effects of PON2 overexpression was abolished by inhibition of 
PI3K. CRC was significantly reduced in the H9c2-hPON2 cells when compared to H9c2-
EV control [105±5 in H9c2-EV+PI3Ki, 60±10 in H9c2-hPON2+PI3Ki, nmoles of Ca2+ per 
1.5x106 cells, p<0.05] (Figure 5B). PI3K inhibitor treated H9c2-hPON2 cells also 
displayed reduced CRC compared to non-PI3k inhibitor treated H9c2-hPON2 cells 
[200±14.43 in H9c2-hPON2 w/o, 60±10 in H9c2-hPON2+PI3Ki, nmoles of Ca2+ per 
1.5x106 cells, p<0.0001]. Following PI3K inhibition, H9c2-hPON2 cells exposed to HRI 
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had 50% more mitochondrial ROS production when compared to H9c2-EV controls with 
inhibitor (p<0.01) and approximately 100% increase when compared to the H9c2-PON2 
cells without inhibitor (Figure 5D). Lastly, H9c2-PON2 cells treated with PI3K inhibitor 
had a highly significant increase in apoptosis when compared to the H9c2-hPON2 cells 
alone [80% TUNEL positive H9c2-hPON2+PI3Ki versus 5% in H9c2-hPON2, p<0.0001] 
(Figure 5F). No differences in cell apoptosis were observed at baseline (untreated) 
conditions (Supplemental Figure 4).  
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2.4 Discussion 
 Myocardial IRI is a highly complex disease characterized by both an ischemic 
injury, resulting from the occlusion of the coronary arteries, and a paradoxical 
reperfusion injury following the return of blood flow to the myocardium. During 
reperfusion, calcium overload and ROS production trigger mitochondrial membrane 
depolarization, uncoupling of oxidative phosphorylation, and release of cytochrome c to 
the cytosol initiating caspase induced apoptosis and the death of CM.15, 16, 18 Therefore, 
mitochondrial dysfunction and oxidative stress are fundamental components of 
myocardial IRI pathogenesis.  
PON2 plays a protective role in many disease models including atherosclerosis, 
neurodegenerative disorders, ovarian cancer, and cardiovascular disease. PON2’s 
ability to modulate mitochondrial dysfunction and oxidative stress serves as an 
underlying mechanism for protection against these diseases.4, 7, 62, 63 While the role of 
PON2 in IRI has not been previously investigated, we found that PON2 is upregulated in 
WT mouse hearts following in vivo IRI. As PON mitigates mitochondrial dysfunction, ER 
stress and maintains calcium homeostasis, upregulation of PON2 may help the 
myocardium protect against IRI. As such, we investigated the role of PON2 in conferring 
protection against acute IRI and its potential as a therapeutic target.  
Our study demonstrates that PON2 expression is inversely related to IRI severity 
as PON2-def mice subjected to IRI exhibited a significant increase in infarct size when 
compared to WT controls (Figure 1D-E). Since mitochondrial dysfunction and oxidative 
stress are hallmark consequences of myocardial IRI, we tested the mitochondrial 
integrity of PON2-def mice following IRI.4-5 Our findings reveal that PON2-def mice have 
26 
 
an inherent mitochondrial defect that, when in the presence of an exogenous stressor 
(i.e. extramitochondrial calcium), manifests into basal mitochondrial dysfunction (Figure 
2B). Furthermore, mitochondria isolated from PON2-def mice subjected to IRI had a 
significant reduction in CRC (Figure 2A/B) and oxidative stress (Figure 2C/D), when 
compared to WT controls. We further examined and validated these results specifically 
within mitochondria from the CM subpopulation (Figure 3). These observations 
demonstrate a clear role for PON2 in protection against myocardial IRI as lack of PON2 
results in increased IRI, in the form of mitochondrial dysfunction and oxidative stress. 
In addition, we determined that the cardioprotective capacity of PON2 is 
intimately connected to the RISK pathway (PI3K/Akt/GSK-3β), a fundamental 
cardioprotective pathway involved in mitigating myocardial IRI.7-9 We previously 
demonstrated a connection between PON2 deficiency and impaired PI3K/Akt activation 
when treated with 3OC(12)-HSL, a quorum-sensing molecule.64 Therefore, we sought to 
further explore the role of PON2 in modulating myocardial IRI via the RISK pathway. We 
observed that PON2 deficiency resulted in a significant decrease in cardioprotective 
pGSK-3β levels in the heart of PON2-def mice subjected to myocardial IRI (Figure 2G-
H). Conversely, overexpression of PON2 sufficiently increases pGSK-3β levels and 
rescues mitochondrial dysfunction and oxidative stress in H9c2 cells, a model 
cardiomyocyte cell-line, when subjected to HRI (Figure 4-5). This protection conferred 
by PON2 overexpression is abolished in the presence of LY294992, a potent PI3K 
inhibitor (Figure 5).  
Many studies demonstrate that mitochondrial phospholipids, particularly outer 
and inner mitochondrial membrane phospholipids like cardiolipin, play a vital role in 
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maintaining mitochondrial homeostasis by aiding in protein biogenesis and maintaining 
normal bioenergetics, membrane function and apoptosis.26, 35 These mitochondrial 
membrane phospholipids are susceptible to oxidative damage during IRI, which leads to 
lipid peroxidation, loss of IMM organization and a decrease in cardiolipin content and 
peroxidation, which in turn leads to poor electron flow, further generation of ROS, and 
impairment of respiratory complexes and membrane potential.27, 28, 35-38 As noted earlier, 
PON2 is localized within the IMM and has a capacity to attenuate cardiolipin 
peroxidation, cytochrome c release, and caspase activation.5, 49 PI3K, which exerts its 
effects through the membrane lipid phosphatidylinositol, is associated with a plethora of 
cell signaling, membrane trafficking and metabolic processes.65 In particular, PI3K/Akt 
signaling has been implicated in cell survival, particularly through intervention in 
mitochondrial apoptosis via inhibition of cytochrome c release and caspase activation.66-
68 The intimate connection and shared function between PON2 and PI3K/Akt  may 
explain the molecular mechanism of PON2 cardioprotection by modulating 
mitochondrial membrane homeostasis and apoptosis, although further studies are 
needed to confirm our hypothesis.  
Additionally, X-ray crystallography studies performed on PON1, a paralogue of 
PON2 that shares 65% amino acid homology, revealed a fatty acid tail binding substrate 
pocket.69 We previously demonstrated that PON2 binds Coenzyme Q10, which has a 
fatty acid tail and is synthesized in the IMM.5 Moreover, mitochondrial membrane 
phospholipids, like cardiolipin, contain fatty acid tails that may bind this substrate 
pocket, and preliminary experiments from our lab demonstrate direct binding of 
cardiolipin and PON2.70 A future direction of study includes investigating the effect of 
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PON2 in modulating mitochondrial membrane phospholipid composition during 
myocardial IRI.  
The role of calcium in modulating IRI is fundamental to the pathogenesis of the 
disease. As such, there are many pathways involved in maintaining calcium 
homeostasis in the myocardium including the GSK-3β pathway.71 A recent study by 
Gomez et al demonstrated a connection between GSK-3β and ER-mitochondria calcium 
regulation during IRI, specifically that GSK-3β localizes at the ER and mitochondria-
associated ER membranes (MAMs) and, at the MAMs interface, it regulates IP3R 
calcium transfer between the ER and mitochondria.22 mPTP is a nonselective channel 
of the IMM, and its opening results in mitochondrial membrane depolarization, 
uncoupling of oxidative phosphorylation, release of cytochrome c to the cytosol and 
activation of the caspase cascade leading to cardiomyocyte death.15, 16, 18 In addition, a 
key organelle responsible for calcium homeostasis is the ER.72 Not only does our data 
show the connection between PON2 and GSK-3β in myocardial IRI, but we also 
demonstrate that PON2-deficiency leads to an increase in CHOP (Figure 2E-F), an ER 
stress marker responsible for IP3R-calcium release from the ER and initiating cell 
apoptosis, among other deleterious consequences. Conversely, overexpression of 
PON2 in H9c2 cells subjected to HRI results in a significant reduction in CHOP 
expression (Figure 4C-D). Our lab previously demonstrated the that PON2 deficiency in 
macrophages results in increased expression of CHOP and dysregulation of calcium 
homeostasis under ER stress conditions.46, 47 Consequently, the role that PON2 could 
play in regulating calcium homeostasis at the MAMs interface via GSK-3β modulation 
warrants further investigation. 
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Our study is the first to identify the robust protective role of PON2 in acute IRI. 
PON2 deficiency in CM leads to increased mitochondrial dysfunction and oxidative 
stress, which is rescued by PON2 overexpression, reflecting its potential therapeutic 
potential. Furthermore, attenuation of this rescue by PI3K inhibition highly suggests a 
casual role that the RISK pathway (PI3K/Akt/GSK-3β) plays as a potential molecular 
mechanism of PON2 cardioprotection against IRI.  
 
 
 
2.5 Conclusion 
• PON2 deficient mice have a 2 fold larger infarct size following myocardial IRI. 
• PON2 deficiency in cardiomyocytes leads to an increase in mitochondrial 
dysfunction (reduced calcium retention capacity) and oxidative stress (increased 
ROS).   
• Cardiac IRI leads to a decrease in cardioprotective phosphorylated GSK-3β 
(pGSK-3β) levels in PON2 deficient mice and an increase in CHOP, an ER stress 
marker. 
• PON2 overexpression rescues mitochondrial dysfunction and oxidative stress 
during IRI, but inhibition of PI3K ablates PON2’s cardioprotective properties. 
• The RISK (PI3K/Akt/GSK-3β) pathway acts a potential molecular mechanism for 
PON2 cardioprotection.  
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Figure 1A 
 
 
 
 
 
 
 
 
 
 
Figure 1B 
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Figure 1E 
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Figure 1: PON2 expression is associated with reduced infarct size 
following myocardial IRI. (A) PON2 protein is expressed in both neonatal 
and adult mouse hearts. (B) In vivo myocardial ischemia-reperfusion injury 
(IRI) was induced in PON2-deficent mice (PON2-def) and C57Bl/6, wildtype 
(WT) controls via left anterior descending (LAD) coronary artery occlusion 
for 30 minutes followed by 24 hours of reperfusion. After 24 hours, Evans 
Blue Dye was injected to assess AAR. (C) WT mice were subjected to in 
vivo IRI (n=5) or sham surgery (n=5) and PON2 gene expression levels (as 
fold change) were then determined in the hearts via real-time PCR. 
*p<0.05. (D) Representative Evans Blue Dye-stained heart sections from 
WT and PON2-def mice subjected to in vivo IRI. The white area reflects 
infarcted area, blue area reflects non-infarcted area, and red and white 
areas reflect risk area. (E) Quantification of hearts from WT and PON2-def 
mice (n=8/group) subjected to in vivo IRI assessed by percentage of 
IS/AAR and IS/LV. Data is represented as mean±SEM; *p<0.05. *p<0.05, 
**p<0.01. AAR=area at risk; LV=left ventricle; IS=infarct size. 
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Figure 2A 
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Figure 2E 
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Figure 2G 
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Figure 2: PON2 deficiency leads to global cardiac mitochondrial 
dysfunction and decreased pGSK-3β levels following myocardial IRI. 
(A-F) WT and PON2-def mice were subjected to in vivo IRI (as shown in 
Figure 1B). (A) Representative recordings of the calcium retention capacity 
(CRC) assay from WT and PON2-def mice (n=6/group), which indicates the 
threshold of isolated myocardial mitochondria to extramitochondrial calcium 
on mitochondrial permeability transition pore (mPTP) opening post in vivo 
IRI. CRC was evaluated and quantified as nmoles of calcium per mg of 
mitochondrial protein under baseline (untreated) conditions and under in 
vivo IRI (B). (C) A representative recording of ROS generation, specifically 
H202, from isolated myocardial mitochondria from WT (n=5) versus PON2-
def mice (n=4) post in vivo IRI. ROS generation was quantified as nmole of 
H202 per min per mg of mitochondrial protein and represented as fold 
change under baseline (untreated) conditions and under in vivo IRI (D). 
GSK-3β and pGSK-3β expression was evaluated, as represented in (G), 
normalized to Vinculin, and quantified as a ratio of pGSK-3β to GSK-3β 
(H). CHOP expression was evaluated, as represented in (E), normalized to 
Vinculin, and quantified as a ratio of CHOP to Vinculin (F). Data is 
represented as mean±SEM; *p<0.05.  
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Figure 3A 
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Figure 3C 
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Figure 3E 
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Figure 3F
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Figure 3: Cardiomyocytes deficient in PON2 exhibit increased 
mitochondrial dysfunction, oxidative stress, and apoptosis following 
IRI. (A) Ex vivo ischemia-reperfusion protocol, via the Langendorff Apparatus, 
was performed. Hearts were cannulated onto a Langendorff apparatus and 
allowed to stabilize for 10 minutes with oxygenated, KH buffer. The aorta was 
clamped for 20 minutes, inducing the hypoxic episode, followed by a 5 minute 
reperfusion with oxygenated, KH buffer. (B) ATP levels were assessed in WT 
and PON2-def cardiomyocytes under baseline (untreated) and ex vivo IR injured 
conditions (n=3/group) and represented as relative luminescence units (x104). 
(C) Representative recordings of the calcium retention capacity (CRC) assay 
from cardiomyocytes isolated from WT and PON2-def mice (n=3/group), which 
indicates the threshold of mitochondrial permeability transition pore (mPTP) 
opening of isolated cardiomyocytes to extramitochondrial calcium. (D) CRC was 
evaluated under baseline (untreated) and ex vivo IR injured conditions 
(n=3/group) and quantified as nmoles of calcium per 6.0 x 104 cells. (E) ROS 
generation was evaluated in baseline (untreated) and ex vivo IR injured 
cardiomyocytes (n=3/group) and represented as fold change of mitochondrial 
superoxide production. (F) Apoptosis, evaluated as caspase-3/7 activity, was 
assessed in baseline (untreated) and ex vivo IR injured cardiomyocytes 
(n=3/group) and quantified as relative luminescence units (x104). Data is 
represented as mean±SEM; *p<0.05, **p<0.01, ***p<0.001.  
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Figure 4A  
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Figure 4C 
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Figure 4E 
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Figure 4: Overexpression of human PON2 in H9c2 cells results in 
increased pGSK-3β following HRI. (A) H9c2 cells were stably transfected 
with an empty pcDNA3.1+ plasmid (H9c2-EV) or a pcDNA3.1+ plasmid 
containing human PON2 gene (H9c2-hPON2).  (B) H9c2-EV and H9c2-
hPON2 cells were subjected to hypoxia-reoxygenation injury (HRI) [3-hour 
hypoxia at 2% O2, followed by a 2-hour reoxygenation at normoxic 
conditions]. CHOP expression (n=4/group) was evaluated via western blot 
analysis (C), normalized to vinculin, and quantified as a ratio of CHOP to 
Vinculin (D). GSK-3β and pGSK-3β expression (n=3/group) was evaluated 
via western blot (E), both normalized to GAPDH and then quantified as a 
ratio of pGSK-3β to GSK-3β (F). Data is represented as mean±SEM; 
*p<0.05. 
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Figure 5A 
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49 
 
Figure 5C 
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Figure 5D 
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Figure 5E 
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Figure 5F 
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Figure 5: PON2 overexpression is cardioprotective and activates the 
RISK (PI3K/Akt/GSK-3β) pathway. (A-F) H9c2-EV and H9c2-hPON2 cells 
were subjected to hypoxia-reoxygenation injury ± PI3K inhibitor, LY294002 
(n=3/group). (A) Representative recordings of the calcium retention 
capacity (CRC) assay indicating the threshold of mitochondrial permeability 
transition pore (mPTP) opening of H9c2-EV/hPON2 cells to 
extramitochondrial calcium. (B) CRC was evaluated and quantified as 
nmoles of calcium per 1.5 x 106 cells. (C) Representative measurement of 
mitochondrial superoxide production via live cell analysis using flow 
cytometry. (D) ROS production was quantified and represented as fold 
change of mitochondrial superoxide production. (E) Representative images 
of cell apoptosis, via TUNEL assay (Blue=DAPI and Green=TUNEL 
positive nuclei). (F) Cell apoptosis, via TUNEL assay, was quantified as 
percent of TUNEL positive cells. Data is represented as mean±SEM; 
*p<0.05, **p<0.01, ****p<0.0001. 
 
 
 
 
 
54 
 
Supplementary Figure 1A 
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Supplementary Figure 1B 
 
 
 
Supplemental Figure 1: Heart Function and Structure of PON2-def 
mice are similar to WT at the Baseline. (A) M-mode echocardiograms 
were performed on WT and PON2-def mice (n=3/group) at baseline 
(untreated). (B) LV-EF (%), LV-FS (%), IVS systolic (mm), LV PW diastolic 
and systolic (mm), LV diameter diastolic and systolic (mm), and LV volume 
diastolic and systolic (uL) were evaluated. Data is represented as 
mean±SEM.  
 
 
 LV-EF% LV-FS% 
IVS(mm) 
Diastolic 
IVS(mm) 
Systolic 
LV PW(mm) 
Diastolic 
LV PW(mm) 
Systolic 
WT 63.1±3.45 33.5±2.4 0.6±0.03 0.9±0.03 0.70±0.03 0.99±0.06 
PON2-def 65.0±2.86 35.2±2.2 0.5±0.03 1.0±0.09 0.67±0.04 1.05±0.07 
 
LV Diameter(mm) 
Diastolic 
LV Diameter(mm) 
Systolic 
LV Volume(ul) 
Diastolic 
LV Volume(ul) 
Systolic 
WT 3.1±0.06 2.10±0.07 44.09±4.16 14.30±1.47 
PON2-def 3.31±0.21 2.16±0.16 55.37±4.52 19.71±2.45 
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Supplementary Figure 2A  
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2B 
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Supplemental Figure 2: Heart function and structure of PON2-def mice 
are similar to WT at Baseline. (A) Doppler echocardiograms were 
performed on WT and PON2-def mice (n=3/group) at baseline (untreated). 
(B) E/A ratio: Early (E) to late (A) ventricular filling velocities were 
determined. Data is represented as mean±SEM.  
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Supplementary Figure 3A 
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Supplemental Figure 3: No differences in pGSK-3β levels in H9c2 cell-
lines under baseline conditions. GSK-3β and pGSK-3β levels were 
evaluated via western blot (A), both normalized to GAPDH, and then 
quantified as a ratio of pGSK-3β to GSK-3β in H9c2-EV and H9c2-hPON2 
cells (B) under baseline (untreated) conditions (n=3/group). Data is 
represented as mean+SEM.  
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Supplementary Figure 4A 
 
 
 
 
 
 
 
Supplementary Figure 4B 
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Supplemental Figure 4: No differences in cell apoptosis under 
baseline conditions. Cell apoptosis, via TUNEL assay, was quantified as 
percent of TUNEL positive cells in H9c2-EV and H9c2-hPON2 cells under 
baseline (untreated) conditions (n=3/group). Data is represented as 
mean+SEM.  
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Chapter 3: PON2 Modulates Mitochondrial Lipid Composition and Peroxidation 
via Phosphatidylcholine Oxidation and Production of Eicosanoids and 
Prostanoids  
Abbreviations:  
IMM Inner mitochondrial membrane 
OMM Outer mitochondrial membrane 
CL Cardiolipin 
PC Phosphatidylcholine 
PE Phosphatidylethanolamine 
PUFA Polyunsaturated fatty acids 
CAD Coronary Artery Disease 
IRI Ischemia-reperfusion injury 
MI Myocardial Infarction  
ROS Reactive oxygen species 
WT Wild-type 
PON-def PON2-deficient  
LAD Left anterior descending  
oxPAPC Oxidized 1-palmitoyl-2-arachidonyl-sn- glycero-3-phosphorylcholine 
POVPC 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine 
PGPC 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 
AA Arachidonic Acid 
LA Linoleic Acid 
HETE 5-Hydroxyeicosatetraenoic acid 
HODE 13-Hydroxyoctadecadienoic acid 
cPLA2 Cytoplasmic phospholipase A2 
6-keto PGF1α 6-keto prostaglandin F 1α 
PGE2 Prostaglandin E2 
PGF2α Prostaglandin F2α 
PGD2 Prostaglandin D2 
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3.1 Introduction: 
Many pharmacological interventions that aim to mitigate the negative effects of IRI 
have been largely unsuccessful.20, 21 Therefore, finding a novel molecular modulator that 
is connected to multiple IR pathophysiologies may prove instrumental in the fight 
against myocardial IRI. 
PON2 has been shown to have various anti-oxidant and anti-inflammatory 
properties.4, 5, 44-46 A PON2-deficient mouse model was developed by our lab to test the 
role of PON2 in various disease models.44 PON2 deficiency alters mitochondrial 
function by decreasing mitochondrial complex I and III activity and total ATP levels and 
alters mitochondrial oxidative stress by increasing mitochondrial superoxide production, 
increasing lipid peroxidation and decreasing reduced glutathione levels.5, 45 PON2 is 
localized within the mitochondria, specifically associating with complex III of the IMM.5 
Within the IMM, PON2 attenuated CL peroxidation, cytochrome c release and caspase 
activation.49  
Mitochondrial lipid composition is a vital aspect of maintaining normal 
mitochondrial bioenergetics and function. 35 The major phospholipids in the 
mitochondrial membranes are PC, PE, and CL, which make-up ~40%, 30%, and 15% of 
the total lipids respectively.26 IRI promotes the loss of IMM organization and decrease in 
CL content and peroxidation, which in turn leads to poor electron flow, further 
generation of ROS, and impairment of respiratory complexes and membrane 
potential.35-38 Considering the localization of PON2 within the IMM, earlier, unpublished 
work in our lab sought to investigate whether PON2 associates with CL, a key lipid in 
the IMM.73 Using surface plasmon resonance, it was demonstrated that PON2 binds to 
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CL in a concentration-dependent manner (Figure 6A).73 In addition, the ability of PON2 
to further interact with cardiolipin and potentially aid in its transport across the inner and 
outer mitochondrial membranes was tested. The fluorescent probe octadecyl-rhodamine 
(R18) was used as a marker for cardiolipin. Transfer of R18 was examined from R18 
labeled vesicles that mimic the IMM (DOPC:DOPE:TOCL [1:1:1]) to either another set 
of unlabeled IMM vesicles or to a set of vesicles mimicking the composition of the OMM 
(DOPC:DOPE:DOPS:bbPI:TOCL[38:28:9:9:4]). The results demonstrated that PON2 
indeed transports CL from the IMM to the outer mitochondrial membrane (OMM) (Figure 
6B).  
Mitochondrial membrane lipids like phospholipids phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), and cardiolipin (CL), contain esterified polyunsaturated 
fatty acids (PUFAs), particularly arachidonic acid (AA) and linoleic acid (LA), that are 
susceptible to oxidative damage during myocardial IRI leading to lipid peroxidation.33, 74 
Furthermore, these AA and LA PUFAs can be unesterified by phospholipases and 
oxidized into potent lipid signaling molecules like eicosanoids and prostanoids, which 
play significant inflammatory and anti-inflammatory roles in a variety of diseases, 
including myocardial IRI.29, 33, 34, 75, 76 
We have shown that PON2 is present in cardiomyocytes, localized in the IMM,5 
binds to CL and transports CL from the IMM to the OMM. These data support the 
hypothesis that PON2 does associate with mitochondrial membrane lipids and can 
potentially play a role in modulating lipid composition against IRI. Therefore, I 
hypothesize that PON2 plays a protective role against IRI in cardiomyocytes by 
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modulating mitochondrial lipotoxicity, in the form of lipid composition and lipid 
peroxidation. 
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3.2 Materials and Methods 
3.2.1 Experimental Mice  
C57BL/6J, wild-type (WT) mice and PON2 deficient (PON2-def) male mice 8-10 
weeks of age were used for the in vivo studies. The wild type controls used for all our 
studies were derived from PON2 heterozygous intercrosses. All animal studies were 
approved by the IACUC and Animal Research Committee (ARC) at UCLA, and 
designed to prevent/reduce any stress/pain. 
3.2.2 H9c2 Cell Culture Methods 
H9c2(2-1) (ATCC CRL-1446), a rat ventricular cardiomyocyte cell-line, was 
utilized for the in vitro studies. ATCC-formulated DMEM (catalog#30-2002, ATCC) was 
used to culture the cells, with the addition of 10% FBS (Catalog#26140079, 
ThermoFisher) and 1% Penicillin-Streptomycin (catalog#15140122, ThermoFisher) for 
complete growth medium. H9c2 cells were transfected with pcDNA3.1+ plasmid 
expressing human PON2 (H9c2-hPON2) or empty vector (H9c2-EV) (Catalog#V790-20, 
Addgene) using Lipofectamine 2000 transfection reagent (catalog#11668027, 
ThermoFisher). Stable cell-lines were generated by selection of positive colonies via 
neomycin selection (Geneticin, catalog#10131035, ThermoFisher).  
3.2.3 Ischemia-Reperfusion Injury 
In vivo IRI  
Left Anterior Descending (LAD) Coronary Artery Occlusion: Mice were subjected 
to vivo IRI as previously described.57 In brief, mice were anesthetized with ketamine 
(100 mg/kg i.p.) and xylazine (10 mg/kg i.p.). After general anesthesia, the baseline 
ECG and ECHO were performed. Under mechanical ventilation, the chest was opened 
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and the heart exposed. A suture was placed around the left anterior descending 
coronary artery (LAD) three quarters of the distance from the base to the apex, and 
tightened to occlude the LAD permanently for 30 minutes, which was confirmed by ST 
elevation in ECG. The ligature was released to start reperfusion. The chest was then 
closed and the mice were allowed to recover. Twenty-four hours later, the mice 
were euthanized using approved procedures and the hearts removed for downstream 
lipid extraction.   
In vitro IRI 
Hypoxia-Reoxygenation via Hypoxia Chamber: To induce hypoxia in cells, cell 
media was changed from normal, growth media (refer to H9c2 Cell Culture Methods) to 
a low nutrient DMEM (Life Technologies, Catalog# 11966-025) without growth factors 
and were placed into a hypoxic plastic chamber under hypoxic gas conditions (0% O2, 
5% CO2, nitrogen balanced) at 37oC for 3 hours. Hypoxia was confirmed by HIF-1α 
upregulation (data not shown). The cells were then reoxygenated by replacing the 
media back to regular growth media and placing the cells back to normoxic gas 
conditions (~20-21% O2 and 5% CO2) at 37oC for 2 hours. The cells were then used for 
all downstream assays.  
3.2.2 Mitochondrial Isolation from Heart Tissue 
Fresh relaxation buffer (55.5mg Sodium Pyrophosphate, 5 ml KCL 1M, 500ul 
EGTA 500mM, 250ul HEPES 1M, Add 40ml milliQ water, pH to 7.4, and adjust final 
volume to 50ml) was prepared. Mice were anesthetized using isoflurane and sacrificed 
the animal by cervical dislocation. Hearts were removed then immediately immersed 
heart in 3ml ice cold relaxation buffer on a 6 well plate (on ice). The hearts were 
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incubated in the solution for 3-5 minutes, pressing/squeezing the heart with tweezers to 
remove blood from inside the heart. Hearts were moved to next well with clean 
relaxation buffer and repeated heart perfusion is continued as detailed above. Lastly, 
hearts were moved to third well containing 2 mL of ice cold homogenization solution 
(4.28g Sucrose (0.25M), 30ml milliQ water, 250ul HEPES 1 M (5mM), 100ul EDTA 500 
mM (1mM), pH to 7.4, with 1M KOH), and water adjusted to 50ml. The heart was 
minced to approximately 0.5cm (very small) pieces. The heart pieces were collected 
with tweezers and transferred to ice-cold Glass Teflon homogenizer (Fisher) with 2ml of 
ice cold homogenization solution. 20 Strokes were performed (up and down IN ICE) 
with the loose pestle. Homogenates were transferred to glass on glass homogenizer 
and another 20 strokes were performed with tight pestle in ice. A homogenous solution 
should be seen. The homogenate is centrifuged in 2 mL Eppendorf tubes at 900 xg for 
10 minutes in centrifuge (4oC). The pellet is discarded and the supernatant is collected, 
which contains the mitochondria (avoiding pellet), and transferred to a fresh 2ml 
Eppendorf tube. The supernatant is centrifuged at 9000xg for 15 minutes (4oC). A pellet 
containing the mitochondria should be seen. Supernatant is carefully removed, avoiding 
sucking up the pellet. The pellet in resuspended in 100 µl of water (HPLC-grade water) 
and protein concentration is measured via Bradford Assay.  
3.2.3 Phospholipid Extraction  
Equal mitochondrial protein is added from each sample and volume is adjusted 
to 100 µl with more HPLC grade water into a new glass tube (13x100mm) and then 
another 200 µl of HPLC grade water is added (total 300 µl). 1.8 mL of 2:1 CHCl3:MeOH 
(HPLC grade) is added to each glass tube in addition to 20 µl of 20 mM BHT and 5 µl of 
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internal standard mixture (Kansas Lipidomics). Samples are vortexed for 30 seconds 
and then centrifuged at 1000 rpm for 10 minutes to separate phases. The organic layer 
(bottom phase) is transferred so that the aqueous layer is excluded to a new tube 
(13x100mm). 600 µl MeOH and 1.2 ml water are added. Sample are vigorously 
vortexed for 30 seconds and centrifuged at 1000rpm for 10 minutes. The organic phase 
(lower phase) is harvested and transferred to a new tube (12x75mm). Samples are 
dried under Argon and resuspended in 100 µl HPLC-grade MeOH and transferred into 
1.5ml Eppendorf tubes and centrifuged at 13,600 rpm for 10-15 minutes to remove any 
potential debris. 50 µl of supernatant were transferred into a labelled mass spec vial. 
Sample were either ready to be run on mass spectrometer or stored at -80oC for future 
run.51 
3.2.4 Lipid Extraction for Lipid Panel from Mitochondria Isolated from Heart Tissue and 
Cells 
Equal mitochondrial protein is added from each sample and volume is adjusted 
to 100 µl with more HPLC grade water into a new 1.5 ml Eppendorf tube and then 
another 200 µl of HPLC grade water is added (total 300 µl). 5 µl of BHT (10mM) and 
20ul of 5x Lipid Panel IS mix (final concentration 10ng/ml extract) is added. 180ul 
MeOH is added, and the sample are vortexed well (30 seconds minimum). Samples are 
centrifuged at 13,000rpm for 10 minutes, and supernatant is transferred to 13x100mm 
glass tube. 2.5ml of acidified HPLC grade water (pH 3-4) is added to the tubes and 
vortexed. Supernatant were extracted using 3 cc Oasis HLB SPE cartridge on manifold: 
Cartridges are activated with 2 ml HPLC-grade MeOH; Washed with 2 ml H2O; 
Samples were then added to cartridge, Washed with 2 ml 5% MeOH (HPLC-grade); 
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Final collection tubes (13x100mm glass) were placed into manifold; and finally the 
samples were eluted with 2 ml 100% HPLC-grade MeOH. Samples were dried to 
completion under argon in 37oc water bath. Samples were then reconstituted with 100 µl 
HPLC-grade MeOH and transferred to a labelled 1.5ml Eppendorf tube. Tubes are 
centrifuged at 13,600rpm for 10 minutes at 4oC. 50 µl of the sample were transferred to 
labelled mass spec vials and delivered for analysis. Remainder of samples are stored in 
Eppendorf tube at -80oC under argon atmosphere.51  
3.2.5 Mitochondrial Lipid Saponification  
Mitochondrial samples were thawed in their original Eppendorf tubes and any 
remaining solvent were evaporated under argon/N2. 1ml of MeOH is added, and then 
vortexed/sonicated and then the supernatant was transferred to 16ml screw-top glass 
tubes. 50ul of 50% KOH (made with HPLC-grade water) was added, vortexed, and 
capped. The samples were then heated in 60oC water bath or oven for 1 hour. The 
reaction was arrested by cooling in ice water bath briefly, then adding 450 µl of 1M HCl 
(made with HPLC-grade water), and vortexed. 1 ml HPLC-grade Hexane was added, 
tubes capped, and vortexed for 30 seconds. Tubes were centrifuged for 10 minutes at 
2000rpm until 2 distinct layers were seen. The lower organic layer was transferred using 
a glass Pasteur pipet to a new 13x100mm tube. The organic layer were completely 
dried down under argon. Samples were then reconstituted with 180 µl of HPLC-grade 
MeOH. Lipid signals were extracted using lipid extraction for panel method, as noted 
above.  
3.2.6 OxPAPC Lipid Extraction from Mitochondria Isolated from Heart Tissue and Cells 
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Equal mitochondrial protein were added from each sample and the volume 
adjusted to 100 µl with more HPLC grade water into a new 1.5 ml Eppendorf tube and 
then the following were added: 600 µl of HPLC-grade 1-butanol, 30 µl of internal 
standard mix (500 ng/ml), and 400 µl brine (10% NaCl made with HPLC-grade water). 
Samples were vortexed for 1 minute and centrifuged at 2000rpm for 10 minutes. Upper 
organic phase were transferred to new 12x75mm glass tubes and the butanol was 
evaporated under argon. Samples were reconstituted with 150 µl HPLC-grade MeOH 
and transferred to a labelled 1.5ml Eppendorf tube. Tubes were then centrifuged at 
13,600rpm for 10 minutes. 50 µl of the sample were then transferred to labelled MS Vial 
and delivered for analysis. The remainder of samples were stored in Eppendorf tube at -
80oC under argon atmosphere.51 
3.2.7 LC-MS/MS Methods 
Lipid Panel and oxPAPC Panel 
The LC-MS/MS methods utilized for the lipid and oxPAPC panels were adopted 
from Meriwether, et al., as previously described.51 
Phospholipid Analysis 
We modified a method outlined by Vu, et al., for our initial baseline mitochondrial 
membrane phospholipid characterization.77 For our subsequent evaluation of the 13 
lipid classes post-IRI, we utilized the services of the UCLA Lipidomics Core, which uses 
the following method: “This is a mass spectrometry-based approach that involves direct 
infusion of lipid samples into the AB SCIEX Lipidyzer Platform: a SCIEX 5500 triple-
quadrupole (QQQ) with a Shimadzu auto-sampler configured for direct infusion 
experiments, SelexION ion mobility device, and Shimadzu LC. Backend analysis is 
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performed using Sciex proprietary Lipidyzer software. When combined with SCIEX’s 
proprietary lipids standard sets, this instrument can provide accurate, quantitative 
measurements of over 1000 lipid species across 13 lipid classes within a biological 
sample.” (this method is taken directly from the website of the UCLA Lipidomics Core 
[https://www.uclalipidomics.net/services-755110.html]). 
3.2.8 Statistical Analysis 
Student’s t-tests were carried out between all studies with two groups. Data from 
experiments with more than 2 or more groups were compared using a one-way ANOVA 
model. After a significant overall group effect was established, Tukey’s pairwise 
comparisons were carried out to determine specific group to group differences. All data 
is represented as mean±SEM. A p-value less than 0.05 was considered statistically 
significant. 
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3.3 Results 
3.3.1 PON2 deficiency alters mitochondrial membrane phospholipid composition. 
To determine if PON2 deficiency inherently affects the mitochondria membrane, 
specifically the phospholipid composition, I sought to characterize the mitochondrial 
membrane phospholipid composition in WT and PON2-def mice (n=4/group) under 
baseline conditions (Figure 7). Mitochondria were isolated from both WT and PON2-def 
mice and phospholipids were extracted. The phospholipid composition, including 
various acyl chain combinations, of LPC, PC, PE, PG, PI, and PS was determined via 
LC-MS/MS. Many PC species were significantly reduced compared WT controls (Figure 
7A), while PE had one species (42:9) that was significantly elevated (Figure 7B). There 
were no significant changes observed between the groups for PG, PI, and PS (Figure 
7C-E).  
Subsequently, I wanted to evaluate the phospholipid changes in both WT and 
PON2-def mice (n=4/group) post-IRI. 13 lipid classes were then evaluated in the 
mitochondria from the heart of these mice, along with the whole heart lysate generated 
during the mitochondria isolation process, via LC-MS/MS, as summarized in 
Supplemental Figure 5. Triglyceride levels were significantly down in the mitochondria 
and whole hearts of PON2-def mice versus WT controls (Supplementary Figure 5). 
Furthermore, when exploring specific lipid species, many PE and PC species containing 
linoleic acid (LA, 18:2) or arachidonic acid (AA, 20:4) esterified as one or both of their 
associated fatty acids were significantly increased in the PON2-def mice versus WT 
controls (Figure 8). Due to variation of the phospholipid classes and the increased 
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oxidative stress that occurs during myocardial IRI, I sought to further characterize and 
explore the potential lipid peroxidation that could be occurring in PON2-def mice.  
3.3.2 Mitochondrial lipids experience increased oxidation under baseline conditions in 
PON2-def mice 
 Prior to exploring the role that PON2 deficiency has on mitochondrial lipid 
peroxidation, I characterized the mitochondrial lipid peroxidation in WT and PON2-def 
mice (n=6/group) under baseline conditions (Figure 9). Initially, free, unbound lipids 
(pre-saponification) were evaluated. Subsequently, the mitochondrial preps were 
saponified (post-saponification), releasing all the bound fatty acids from their respective 
phospholipids. Various oxidized lipids were measured, including oxidized metabolites of 
linoleic (HODEs) and arachidonic (HETEs) acid were measured. I observe that there 
was a significant increase in eicosanoid products (5-HETE, 12-HETE and 5-oxoETE) 
and oxidized LA metabolites (9-HODE and 13-HODE) in the mitochondria of PON2-def 
mice pre-saponification (Figure 9A) as well as 11-HETE and 12-HETE (p=0.052) post-
saponification (Figure 9B), compared to WT controls. Lastly, oxidation of mitochondrial 
phospholipids was assessed, specifically measuring the levels of two prominent 
oxidized products of PC, POVPC and PGPC. I observe that there was a significant 
increase in both POVPC and PGPC in the mitochondria of PON2-def mice versus WT 
controls (Figure 9C). 
 Having determined that there is an inherent susceptibility for oxidation in 
mitochondrial lipids of PON2-def mice, I investigated the effects of this phenotype 
during IRI as well as measuring any further mitochondrial lipid peroxidation.  
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3.3.3 PON2 deficiency leads to increased mitochondrial lipid peroxidation during 
myocardial IRI 
To study the effects that myocardial IRI has on mitochondrial lipids, WT and 
PON2-def mice (n=4/group) were subjected to IRI. The mitochondria were isolated from 
the hearts of the mice and lipids were extracted, both pre-saponification and post-
saponification. Various eicosanoid products, including oxidized metabolites of LA 
(HODEs) and AA (HETEs) were measured. I observe that in the pre-saponified 
mitochondria, there is a significant increase in 12-HETE and 15-HETE, while 9-HODE 
significantly decreases in the PON2-def mice versus controls (Figure 10A). Moreover, 
15-HETE is significantly increased post-saponification in the myocardial mitochondria of 
PON2-def mice when compared to WT mice (Figure 10B). When evaluating 
phospholipid oxidation, POVPC is significantly increased in the mitochondrial hearts of 
PON2-def mice versus WT controls.   
Given the consistent oxidation of lipids, specifically arachidonic acid, and PC in 
the myocardial mitochondria of PON2-def mice (versus WT), I sought to determine 
whether overexpression of PON2 can rescue any of these oxidative phenotypes.  
3.3.4 PON2 overexpression has the capacity to partly rescue mitochondrial lipid 
oxidation post-IRI  
 H9c2 cells stably expressing EV or hPON2, as described in chapter 2, were 
utilized to test the protective role that PON2 overexpression could have against 
mitochondrial lipid peroxidation. These cells were subjected to HRI and lipid 
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peroxidation was assessed (Figure 11). H9c2-hPON2 cells have significantly reduced 
12-HETE (Figure 11A) and POVPC (Figure 11B) levels versus EV controls.  
 These data suggest the protective role that PON2 plays in mitigating oxidation of 
mitochondrial lipids. Next, I sought to investigate what potential mechanisms could be 
underlying this protection against myocardial IRI.  
3.3.5 Cytoplasmic PLA2 and prostanoids levels potentially mediate PON2 protective 
role against mitochondrial peroxidation post myocardial IRI.  
 I sought to probe the mechanisms behind the changes observed in phospholipid 
composition and the production of eicosanoids in the mitochondria of my in vivo and in 
vitro IRI experiments by examining cytoplasmic PLA2 and downstream production of 
pro-inflammatory/pro-resolving prostanoids. I examined the expression of cytoplasmic 
PLA2 (cPLA2) protein levels by western blot, on whole heart lysates from PON2-def 
mice and WT mice (n=4/group) subjected to myocardial IRI (Figure 12). There is a 
significant increase of cPLA2 levels in the PON2-def hearts versus WT controls as seen 
in Figure 12A, and as quantified in Figure 12B. Furthermore, when examining the 
prostanoid production, specifically of prostaglandins (PGE2, PGF2α, and PGD2) and 
prostacyclin (6-keto PGF1α), I observe that 6-keto PGF1α, PGE2, PGF2α, and PGD2, 
are all significantly decreased in the myocardial mitochondria of PON2-def mice when 
compared to WT controls (Figure 12A). However, the opposite is observed in the H9c2-
hPON2 cells, with a significant increase in 6-keto PGF1α and PGE2, when compared to 
EV controls. This data suggests that PON2 plays a role in modulating phospholipid 
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composition by modulating cPLA2 levels as well as influencing the production of various 
pro-inflammatory/pro-resolving prostanoids during myocardial IRI.  
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3.4 Discussion 
This study aimed to explore the role that PON2 plays in modulating mitochondrial 
lipid composition and peroxidation. Initially, I characterized the baseline changes of the 
mitochondrial phospholipid composition between WT and PON2-def mice. I observed 
that there is significant decrease in PC species and an increase in one PE species in 
the myocardial mitochondria of PON2-def mice versus WT controls, with no significant 
differences in PG, PI, or PS levels (Figure 7A-E). Moreover, when evaluating any 
mitochondrial lipid changes post-IRI, I observed that the trend towards increased PE 
species held true, with a significant increase in various PE species, while one PC 
species increased (Figure 8). Of note, the polyunsaturated fatty acids (PUFA) esterified 
into these membrane phospholipids are linoleic acid (18:2) and AA (20:4). Moreover, 
the oxidation of these particular PUFAs, under conditions of oxidative stress or 
enzymatically via cyclooxygenase and lipoxygenase, results in the formation of 
eicosanoids and prostanoids, both of which are critical signaling molecules affecting a 
host of inflammatory responses in various disease models, including CVD and 
myocardial IRI.33, 51, 78  
Consequently, I investigated the role that PON2 plays in modulating the levels of 
free, unesterified (pre-saponification) and esterified (post-saponification) mitochondrial 
lipid peroxidation of PUFAs. Interestingly, I found that even under baseline conditions, 
PON2-def mice were more susceptible to oxidation of AA with significantly increased 
unesterified 15-HETE (Figure 9A) and esterified 12-HETE (Figure 9B) versus controls. 
Furthermore, there is a significant increase in unesterified 12-HETE and 15-HETE 
(Figure 10A) and esterified 15-HETE (Figure 10B) post-IRI in the myocardial 
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mitochondria of PON2-def mice compared to WT controls. Additionally, PON2 
overexpression decreased the levels of unesterified 12-HETE in H9c2 cells subjected to 
HRI (Figure 11A). Although PON2 deficiency increases oxidation of AA into these 
various eicosanoids, it remains unclear what specific lipoxygenases are being 
modulated by PON2 as well as the contribution of non-enzymatic oxidation by way of 
ROS, both of which remain to be elucidated. Next, I examined the role that PON2 plays 
in modulating prostanoids during myocardial IRI.  
Many studies have demonstrated the cardioprotective effects that various 
prostanoids have against cardiovascular disease, including myocardial IRI.34, 76 For 
example, both endogenous PGE2 and exogenous EP4 agonists protect the heart from 
IRI via EP4, in which EP4-/- mice had a larger infarct size in the heart compared to WT 
controls.29 These protective effects were in part by PGE2 inhibitory effects on neutrophil 
function and regulation of the production of various inflammatory cytokines, like TNFα 
and IL-10, in macrophages via EP4.29 In addition, PGI2, and its downstream metabolites 
including 6keto-PGF1α, have been shown to reduce the infarct size in dog hearts, and 
pig hearts, both of which demonstrated that the cardioprotective effects were in part 
mediated to inhibition of neutrophil migration.31, 32 In this study, I observe that PON2 
deficiency in myocardial IRI leads to a significant decrease in mitochondrial prostanoid 
levels (6-keto PGF1α, PGE2, PGF2α, and PGD2) (Figure 12A), while overexpression of 
PON2 in H9c2 cells subjected to HRI leads to a significant increase in 6-keto PGF1α 
and PGE2. PON2 deficiency eliminates the cardioprotective effects afforded by 
prostanoid production, while PON2 overexpression can partly rescue the loss. 
Therefore, PON2’s ability to differentially affect prostanoid production supports another 
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potential mechanism of action by which PON2 acts to modulate myocardial IRI, and 
further supports the therapeutic potential of PON2 against myocardial IRI.  
The observed alterations of phospholipid composition and increased levels of 
oxidized PUFAs with differential PON2 expression, specifically unesterified AA 
products, led me to consider the potential role that phospholipase expression could play 
in mediating this response. Cytoplasmic phospholipase 2 (cPLA2), much like the other 
members of the PLA2 superfamily, release free FAs and lysophospholipids from bound 
membrane phospholipids by hydrolyzing the sn-2 ester bond in phospholipids.79 cPLA2 
is located in the cytosol and it’s activation is calcium-dependent (µM) in order to 
translocate to membrane phospholipids where it selectively hydrolyzes arachidonylated 
phospholipids.79, 80 Moreover, cPLA2 activation has also been shown to be activated by 
oxidative stress and has been implicated in an array of oxidative and inflammatory 
pathologies including neurogenerative, cancer, and cardiovascular diseases.79-81 More 
specifically, cPLA2 plays a significant role in modulating myocardial IRI through the 
hydrolysis of cardiac phospholipids resulting in the increased release of unesterified AA 
and subsequent production of various eicosanoids and prostanoids, with some studies 
showing improved cardiac recovery with anti-PLA2 treatment.33, 75, 82, 83 Therefore, I 
evaluated the levels of cPLA2 in PON2-def hearts post-IRI and discovered that cPLA2 is 
significantly increased compared to WT controls (Figure 12). This result sheds some 
light on a potential mechanism of action for the role that PON2 plays in modulating lipid 
oxidation during myocardial IRI, particularly in explaining the increase in mitochondrial 
unesterified PUFA (AA and LA) metabolites in PON2-def mice. Nevertheless, it is worth 
noting that while cPLA2 may explain the increase in release of AA and subsequent 
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eicosanoid levels, the decrease in prostanoid levels seems paradoxical. One possible 
explanation is that PON2 is specifically acting to modulate prostanoid production 
through cyclooxygenase (COX) 1 and 2, the key enzymes responsible for producing 
prostaglandins from AA.51 Given that prostanoid production from AA is largely governed 
by COX, I hypothesize that PON2’s modulation of prostanoids is governed by COX 
activity. In the context of our studies, PON2 deficiency during myocardial IRI inhibits 
COX2 thus reducing prostanoid production; and when PON2 is overexpression, COX2 
is upregulated, increasing prostanoid production. Many papers have shown that COX2 
is protective against myocardial IRI. In fact, recent studies demonstrated the detrimental 
effects of COX inhibition (via NSAIDs) and protective effects of COX2 overexpression 
on myocardial IRI, further supporting this hypothesis.84, 85  However, additional 
dissection of this mechanism of action needs to be undertaken, specifically in 
determining the levels of COX 1 and 2 in my studies.  
Although membrane phospholipids supply the PUFA associated moieties as 
substrates for phospholipases to act on, oxidized phospholipids, like POVPC and 
PGPC, can act as potent mediators of cardiovascular disease.78, 86, 87 A recent study 
demonstrated that there was a significant increase in oxidized phospholipids (including 
POVPC and PGPC) in cardiomyocytes (both cellular and mitochondrial) post IRI.88 
Additionally, treatment with murine IgM natural antibody EO6, which only recognizes 
and bind oxidized phospholipids, attenuated oxidized phospholipid mediated cell death 
and resulted in a reduction of myocardial infarct size when transgenically expressed in 
mice subjected to IRI.88 In this study, I observed that PON2 deficiency results in a 
significant increase of POVPC and PGPC under baseline conditions (Figure 9C), which 
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is then exacerbated following myocardial IRI, with a significant increase of POVPC 
(Figure 10C). Moreover, PON2 overexpression in H9c2 cells results in a significant 
reduction of POVPC during HRI (Figure 11B). This observation, coupled with PON2’s 
ability to reduce eicosanoids and increase prostanoid levels during myocardial IRI, not 
only strengthens the protective role that PON2 can play as a therapeutic agent against 
myocardial IRI.  
Finally, a recent study was just published connecting the association of various 
AA-derived lipid mediators, particularly HETEs, with the ensuing onset of acute MI in 
patients with CAD.74 Our study clearly demonstrates the role of PON2 in modulating 
lipid peroxidation of AA-derived PUFAs, particularly eicosanoids (HETEs), with PON2 
deficiency increasing mitochondrial eicosanoid production post-myocardial IRI. 
Consequently, this study further supports a mechanism of action for explaining the 
increased susceptibility of patients with the human PON2 Ser311Cys (S311C) 
polymorphism for CAD, including myocardial MI.9, 11, 55  
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3.5 Conclusion 
• Under baseline conditions, myocardial mitochondria from PON2-def mice have a 
significant reduction in PC species versus WT controls.  
• There is a significant increase in unesterified and esterified eicosanoids, 
specifically 12-HETE and 15-HETE, as well as increased oxidized phospholipid 
species, POVPC and PGPC, in the cardiac mitochondria of PON2-def mice 
under baseline conditions and post myocardial IRI compared to WT mice. On the 
contrary, PON2 overexpression significantly reduces eicosanoid and oxidized 
phospholipid levels in H9c2 cells post-HRI, compared to EV controls. 
• Cardiac mitochondria from PON2-def mice have significantly decreased 
production of prostanoids post myocardial IRI, while PON2 overexpression in 
H9c2 cells results in significantly increased prostanoid levels post-HRI, compared 
to controls.  
• PON2 deficiency in the heart results in a significant increase of cPLA2 
expression when compared to WT controls.  
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: PON2 binds cardiolipin and transfers it from the IMM to 
OMM. (A) Using surface plasmon resonance, cardiolipin binds PON2 in a 
dose dependent manner. (B) Cardiolipin is transferred from the donor 
(IMM) to the acceptor (OMM) with the additon of 40 nM PON2, while no 
transfer is observed without an acceptor.  
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Figure 7A 
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Figure 7B 
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Figure 7C 
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Figure 7D 
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Figure 7E 
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Figure 7: Mitochondrial Phospholipid Composition of WT and PON2-
def mice under Baseline Conditions.  
Various phospholipid classes and their varying acyl chain compositions, 
were measured from mitochondria isolated from whole hearts of WT and 
PON2-def mice (n=4/group) under baseline conditions using LC-MS/MS, 
including:  (A) Lysophosphatidylcholine/Phosphatidylcholine (LPC/PC), (B) 
Lysophosphatidylethanolamine/Phosphatidylethanolamine (LPE/PE), (C) 
Phosphatidylglycerol (PG), (D) Phosphatidylinositol (PI), and (E) 
Phosphatidylserine (PS) were measured from. Concentrations of the 
phospholipids are in µg/ml. Data is represented as mean±SEM and 
statistically significant data is noted as *p<0.05. 
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Figure 8: Mitochondrial Phospholipid Composition of WT and PON2-
def mice post-IRI. Various phospholipid classes and their varying acyl 
chain compositions, were measured from mitochondria isolated from whole 
hearts of WT and PON2-def mice (n=4/group) post-IRI using LC-MS/MS, 
including:  (A) Lysophosphatidylcholine/Phosphatidylcholine (LPC/PC), (B) 
Lysophosphatidylethanolamine/Phosphatidylethanolamine (LPE/PE), (C) 
Phosphatidylglycerol (PG), (D) Phosphatidylinositol (PI), and (E) 
Phosphatidylserine (PS) were measured from. Concentrations of the 
phospholipids are in µg/ml. Data is represented as mean±SEM and 
statistically significant data is noted as *p<0.05. 
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Figure 9A 
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Figure 9B 
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Figure 9C 
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Figure 9: Mitochondrial phospholipid and lipid oxidation products in 
WT and PON2-def mice under baseline conditions. Mitochondrial lipids, 
specifically oxidized fatty acids derived from linoleic and arachidonic acid 
(11-HETE, 12-HETE, 9-HODE, 15-HETE, 13-HODE, and 5-oxoETE), from 
the hearts of WT and PON2-def mice (n=6/group) under baseline 
conditions were measured via LC-MS/MS both pre-sponification (A) and 
post-sponification (B). Oxidized PC products, POVPC and PGPC, were 
also measured (C). Concentrations of the lipids/phospholipids are in ng/ml. 
Data is represented as mean±SEM and statistically significant data is noted 
as *p<0.05. 
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Figure 10A 
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Figure 10B 
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Figure 10C 
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Figure 10: Mitochondrial phospholipid and lipid oxidation products in 
WT and PON2-def mice post-IRI. Mitochondrial lipids, specifically oxidized 
fatty acids derived from linoleic and arachidonic acid (5-HETE, 11-HETE, 
12-HETE, 9-HODE, 15-HETE, 13-HODE, and 5-oxoETE), from hearts of 
WT and PON2-def mice (n=4/group) under baseline conditions were 
measured via LC-MS/MS both pre-sponification (A) and post-sponification 
(B). Oxidized PC products, POVPC and PGPC, were also measured (C). 
Concentrations of the lipids/phospholipids are in ng/ml. Data is represented 
as mean±SEM and statistically significant data is noted as *p<0.05. 
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Figure 11A 
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Figure 11B 
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Figure 11: PON2 overexpression protects against phospholipid and 
lipid oxidation in H9c2 cells post-HRI. H9c2 cells stably expressing 
either EV or hPON2 (n=4/group) were treated with HRI (0% O2) and lipid 
and phospholipid oxidation was evaluated. 12-HETE levels were 
significantly decreased in the H9c2-hPON2 group versus EV controls (A). 
Furthermore, POVPC was significantly reduced in the H9c2-hPON2 group 
versus EV controls (B). Concentrations of the lipids/phospholipids are in 
ng/ml. Data is represented as mean±SEM and statistically significant data 
is noted as *p<0.05. 
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Figure 12A 
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Figure 12: Cytoplasmic PLA2 expression in WT and PON2-def Hearts 
post-IRI. Cytoplasmic PLA2 (cPLA2) protein expression was determined in 
whole heart lysates from WT and PON2-def mice (n=4/group) post-IRI via 
western blot analysis (A), normalized to vinculin (A), and quantified as a 
ratio of cPLA2 to vinculin (B). The data is represented as Mean ± SEM and 
statistically significant data is noted as *p<0.05. 
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Figure 13A 
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Figure 13B 
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Figure 13: Prostaglandin levels in the hearts of WT and PON2-def 
mice as well as in H9c2 cells (EV vs hPON2) post-IRI. Various 
prostaglandins, including 6-keto PGF1α, PGE2, PGF2α, and PGD2, were 
measured in total heart lysates of WT and PON2-def mice post-IRI 
(n=4/group) (A) and in H9c2 cells (EV and hPON2) subjected to HRI 
(n=4/group) (B) via LC-MS/MS. Concentrations of the prostaglandins are in 
ng/ml. Data is represented as mean±SEM and statistically significant data 
is noted as *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
109 
 
Supplementary Figure 5 
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Supplementary Figure 5: Summary of the 13 lipid classes evaluated in 
both the mitochondria (heart) and whole heart lysates from WT and 
PON2-def mice (n=4/group) post-IRI. Abbreviations: CE- cholesterol 
esters, CER- ceramides, DAD- diacylglycerols, DCER- dihydroceramides, 
FFA- free fatty acids, HCER- hexosylceramides, LCER- lactosylceramide, 
LPC- lysophosphatidylcholines, LPE- lysophosphatidylethanolamines, PC- 
phosphatidylcholines, PE- phosphatidylethanolamines, SM- 
sphingomyelins, TAG- Triacylglycerols. Data is represented as mean±SEM.  
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Chapter 4: Generation of Cardiomyocyte-Specific PON2-KO Mice 
4.1 Introduction  
The PON2-deficient mouse model utilized in our various experiments is a global “knock-
out” of PON2.5, 44, 47 Nevertheless, generating cardiac-specific PON2 knockout mouse 
models allows for the investigation of the role that PON2 plays specifically in the heart, 
while minimizing any off-target or compensatory responses that can arise from the 
global PON2 “knockout” model. Therefore, I intended to generate a colony of cardiac-
specific PON2 knockout mice to enable a robust and effective model for the 
investigation of PON2 in myocardial IRI, as well as other cardiovascular disease 
paradigms. We generated two PON2-cardiac specific knockout mouse models. The first 
is by implementing a PON2 “knockout-first” mouse breeding strategy and the second is 
by utilizing the CRISPR/Cas9 gene editing system. Unfortunately, however, I have not 
been able to test these mice in disease models due to time constraints. Therefore, I will 
be describing in detail the development and partial characterization of these two mouse 
models. Our laboratory will utilize these mice to understand the specific mechanisms 
behind the protective roles of PON2 in mitigating CVD and other related diseases 
described in my thesis. 
4.2 Mice Generation Strategy and Characterization 
4.2.1 PON2 “Knockout-First” Mice Generation 
In order to have the flexibility of generating not only a PON2-cardiac specific 
knockout mouse model, but the potential of any other PON2 tissue specific mouse line, 
we utilized a “knockout-first” reporter tagged insertion allele system, with conditional 
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potential, generated by the EUCOMM/KOMP-CSD ES cell resource.89, 90 We specifically 
used the C57BL/6N-PON2tm1a(EUCOMM)Hmgu mouse, which we obtained from MRC 
Harwell (MGI ID # 4847743) as cryopreserved sperm.  
The cryopreserved sperm came from mice that contain the “knockout-first” allele 
(tm1a). The basic construct for the PON2-Tm1a allele is as follows:  A L1L2_Bact_P 
cassette is inserted at position 5289544 of Chromosome 6 upstream of exon2, 
disrupting gene function. The cassette contains an FRT site followed by a lacZ 
sequence and a loxP site. Following the first loxP site is neomycin (under the control of 
the human β-actin promoter), SV40 polyA, a second FRT site and a second LoxP site. A 
third loxP site is inserted downstream of exon 2 at position 5288760. Exon 2 is thus 
flanked by loxP sites. Therefore, crossing the tm1a mice with Flp recombinase removes 
the gene-trap cassette reverting the mutation to a “wild-type,” conditional allele (tm1c 
allele), restoring gene function and leaving loxP sites on either side of exon 2. 
Subsequent crossing of the tm1c allele mice with tissue-specific cre recombinase allows 
for conditional, tissue-specific knockout of PON2 by deleting the floxed exon2 of the 
PON2-tm1c allele to generate a frameshift mutation (tm1d), causing a nonsense 
mediated decay of the PON2 transcript (Figure 14).89  
The PON2-tm1a mouse line was reconstituted via IVF in a C57BL/6 female. The 
resulting mice are heterozygous for the tm1a allele. We then crossed these mice with 
each other to generate homozygous PON2-Tm1a mice. We are currently breeding 
these mice to generate and expand our PON2-Tm1a homozygous mouse colony.   
Furthermore, we used a Flp recombinase mouse (ROSA26::FLPe knock in, 
stock#: 016226) from Jackson Lab to cross with our PON2-Tm1a mice in order to 
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generate the “wild-type,” conditional knockout ready, Tm1c allele. These mice will serve 
as our experimental wildtype, control group. Furthermore, we generated tm1c 
homozygous mice, with the Flp-recombinase allele crossed out of the genome. We 
have set up breeding between homozygous PON2-tm1c male and female mice in order 
to maintain and expand our tm1c homozygous mouse colony.  
We have acquired a cardiac-specific cre recombinase mouse from Jackson Lab 
(αMyHC-Cre, stock# 011038). This mouse contains a cardiac-specific alpha myosin-
heavy chain (Myh6) promoter, that induces greater than 90% recombination in 
cardiomyocytes, and has no observable recombination in liver, lung, skeletal muscle, 
spleen, or in extraneous cell types in the heart.91 We are currently breeding female 
homozygous PON2-Tm1c mice with our αMyHC-Cre male mouse in order to generate 
the PON2-Tm1d mice, or PON2 cardiac-specific knockout mice. Our breeding strategy 
is as follows: Tm1c (fl/fl) x Cardiac Cre = Tm1c (fl/+)  and Tm1c (fl/+/cre); then Tm1c 
(fl/fl) x Tm1c (fl/+/cre) = Tm1d(fl/fl/cre) and Tm1c(fl/+); lastly Tm1c (fl/fl) x Tm1d (fl/fl/cre) 
= Tm1c (fl/fl) and Tm1d (fl/fl/Cre) (50% each). We have generated PON2-Tm1d, 
homozygous offspring, which will serve as our final Cardiomyocyte-specific PON2 
Knockout experimental mice. 
4.2.2 PON2 “Knockout-First” Mice Genotyping 
Mouse tail biopsies were acquired from pups of potential tm1a, tm1c, and tm1d mice. 
DNA was isolated from tail biopsies and gel based genotyping strategies were utilized to 
confirm the genotypes of the mice.  
Tm1a Gel Based Genotyping:  
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Tm1a gel based assays are designed using a universal mutant reverse primer 
that sits in the sequence just after the 5’ homology arm, or 5mut-R1. A forward primer is 
designed to the 5’ homology arm (PON2-5arm-WTF) and designed to give a mutant 
specific band at 118 bp that will only be present if the cassette is present. Lastly, a 
wildtype (WT) primer (PON2-Crit-WTR) is designed to the critical region and gives a 
product of 288 bp, in the case of a heterozygous, Tm1a mouse. Nevertheless, a Tm1a 
mouse will not produce a WT band, because if the mutant cassette is present the 
product between the two primers is too large to PCR under standard conditions. This 
strategy is summarized in Figure 15.  
Tm1c Gel Based Genotyping:  
Tm1c alleles are produced by exposing tm1a alleles to Flp-recombinase which 
causes the deletion of Neo and LacZ sequences that are between the FRT sites. The 
protocol for Tm1a genotyping needs to be run. Both Tm1a and Tm1c alleles will 
produce a mutant specific product (118 bp) from PON2-5arm-WTF and 5mut-R1. WT 
and Tm1c alleles will produce PCR products from PON2-5arm-WTF and PON2-Crit-
WTR although the Tm1c product (~420 bp) will be bigger due to the presence of the 
FRT-loxP part of the cassette. In addition to this generic Tm1c assay can be used. This 
uses the 5’CAS-F1 and 3’CAS-R1 primers, which will produce a product of 218 bp. This 
strategy is summarized in Figure 16.  
Tm1d Gel Based Strategy:  
Tm1d mice are produced by crossing tm1c animals with mice expressing cre 
recombinase (as outlined above), which causes the deletion of the critical region. The 
tm1d allele produces a 174 bp product from the 5’CAS-F1 and 3’LOXP-R1 primers. A 
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tm1c allele will produce a larger product which includes the critical region sequence. 
Alternatively, in all other tissue types other than cardiomyocytes, Tm1d can be 
confirmed by homozygous Tm1c genotyping and the presence of the αMyHC-Cre allele 
[Tm1c(fl/fl/cre)]. These mice will be considered the experimental mice for downstream 
experiments. This genotyping strategy is summarized in Figure 17.  
A summary of the gel based genotyping assays and list of the correspond 
primers can be found in Figure 18 and Table 1, respectively. 
4.2.3 PON2 “Knockout-First” Mice Characterization  
Two methods were undertaken to characterize the generated mice. The first, as 
mentioned above, was via gel based genotyping screens, as shown in the 
representative images in Figure 19.  
The second method used to assess the genotype of these mice was via 
immunofluorescence. For this approach, Tm1a (homozygous), Tm1c (homozygous), 
and Tm1d mice were euthanized and hearts were collected, paraffin embedded, and 
finally sectioned in a transverse orientation. The sections were then incubated with two 
antibodies, anti-PON2 (Green), anti-sarcomeric alpha actinin (red), and stained with 
DAPI (blue). Representative images are shown below in Figure 20. Tm1a (Figure 20A) 
and Tm1c (Figure 20B) hearts show the expression of PON2 in cardiomyocytes, while 
Tm1d (Figure 20C) hearts show a lack of PON2 expression, demonstrating the 
successful cardiomyocyte-specific deletion of PON2. 
4.2.4 CRISPR/Cardiac-Cas9 Mediated Deletion of PON2 
The CRISPR/Cas9 system of gene editing offers a fast and effective method to 
generate targeted gene editing in many model organisms.92 Consequently, we aim to 
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generate a cardiomyocyte-specific PON2 knock-out mouse model using CRISPR/Cas9 
to investigate and validate the role of PON2 on cardiomyocytes against myocardial IRI. 
4.2.5 Cardiac-Cas9 Mouse/Guide RNA Design and Validation  
A transgenic mouse line has been generated by Dr. Eric Olson’s group at UT 
Southwestern that expresses Cas9 exclusively in cardiomyocytes.93 As a proof of 
concept, Adeno-Associated Virus 9 (AAV9) was used to deliver sgRNA against myosin 
heavy chain 6 (Myh6), via intraperitoneal injection of postnatal cardiac-Cas9 transgenic 
mice, inducing Myh6 editing and resulting in cardiomyopathy and heart failure in the 
mice.93 We have acquired these cardiac-cas9 transgenic mice from Dr. Olson’s group 
and are now breeding and expanding the colony. A representative gel based genotyping 
image is shown in Figure 21, in which a Cardiac-Cas9 positive mice produce a band at 
~700 bp, whereas wildtype mice do not. 
With the acquisition of these mice, we can a generate cardiomyocyte-specific 
PON2 knock-out mouse model by using AAV to deliver sgRNA against PON2, using the 
methods detailed by Olson’s group.93 We have tested four predesigned gRNAs (Table 
2) against mouse PON2 from Integrated DNA Technologies (IDT), using IDT’s patented 
Alt-R CRISPR-Cas9 system to initially validate the potential success of the guides in 
deleting PON2 in vitro via transfection of the guides into NIH/3T3 cells, a mouse 
fibroblast cell-line. 48 hours post transfection, the cells were collected and DNA was 
isolated. The efficiency and efficacy of PON2 deletion was evaluated via the T7 
endonuclease I assay, using the respective PON2 guide RNA primers (Table 3). All 
experimental groups were done in duplicates. Homoduplex and heteroduplex controls 
were also performed successfully. An HPRT positive control worked successfully, 
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producing the expected cleaved products: Full length (647 bp), Fragment 1 (512 bp), 
and Fragment 2 (135 bp). PON2 guides B and C successfully produced the expected 
cleaved products: Full length (925 bp), Fragment 1 (654 bp), and Fragment 2 (254 bp). 
The T7E1 assay results are reflected in Figure 22.  
The efficacy of in vitro mouse PON2 guide RNA deletion was determined by 
evaluating PON2 protein expression post transfection. Guides B and C were chosen to 
be tested as they had the most robust cleavage in the T7E1 assay. Both guides B and 
C were very efficient in knocking out PON2 expression as reflected by the absence of 
the PON2 protein via western blot as seen in Figure 23.  
Lastly, the guides will be cloned into a U6-PON2 gRNA-GFP cassette, which will 
then be cloned into a double-stranded Adeno-associated (AAV) vector plasmid 
backbone that will then be packaged into an AAV9 serotype. Large scale AAV9 viral 
vectors will be produced (~1 x 1013 titer). The Cardiac-Cas9 transgenic mice will then be 
injected with 1 x 1012 viral vectors. Cardiomyocytes will then be isolated and PON2 
deletion will be determined via qPCR and western blot analysis.  
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Figure 14 
Figure 14: A schematic of the breeding strategy for the PON2-tm1a 
allele mice (adopted from Skarnes et al.).89 Tm1a mice bred with Flp-
recombinase mice result in tm1c allele, reverting the mice to “wild-type” 
genotype with loxP site flanking PON2. Further crossing of tm1c mice will 
result in PON2 deletion. Alternatively, if tm1a mice are crossed with cre-
recombinase mice, the resulting mice will have PON2 deleted, with lacZ 
also expressed and can be used to visualize the deletion.  
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Figure 15 
 
Figure 15: Tm1a gel based genotyping strategy (adopted from MHC 
Pon2 HEPD0689_5_E02 Protocol). This generic schematic demonstrates 
the location of the tm1a construct within the gene, in this case PON2, which 
includes the FRT sites and LOXP sites flanking the exons along with the 
location of the primers (denoted as the red and blue arrows) that would be 
used for the gel based genotyping strategy. PON2-5arm-WTF and 5mut-
R1(universal mutant reverse primer) primers will amplify a 118bp product, 
indicating the presence to the Tm1a cassette. Homozygous tm1a will only 
produce the 118 bp. If mouse contains a WT allele (heterozygous), then the 
product between the PON2-5arm-WTF and PON2-Crit-WTR would produce 
a 288 bp product. 
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Figure 16 
 
Figure 16: Tm1c gel based genotyping strategy (adopted from MHC 
Pon2 HEPD0689_5_E02 Protocol). This schematic demonstrates the tm1a 
construct post-Flp recombination, producing the tm1c allele within the gene 
(PON2) and resulting in the deletion of the neomyocin (neo) and LacZ 
sequences between the FRT sites. However, the LOXP sites flank the 
exons and are ready for cre-recombination. The red and blue arrows 
denote the location of the primers that would be used for the tm1c gel 
based genotyping strategy. Tm1a genotyping needs to be run. Tm1c (and 
Tm1a) alleles will produce the mutant specific product of 118bp (PON2-
5arm-WTF and 5mut-R1). WT and tm1c alleles would produce a 288 bp 
product (PON2-5arm-WTF and PON2-Crit-WTR). Lastly, a generic tm1c 
assay (5’CAS-F1 and 3’CAS-R1) will produce a product of 218bp. 
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Figure 17 
 
Figure 17: Tm1d gel based genotyping strategy (adopted from MHC 
Pon2 HEPD0689_5_E02 Protocol). This generic schematic demonstrates 
the tm1d construct post-Cre recombination, which in our studies is the 
excision of PON2. The red and blue arrows denote the location of the 
primers that would be used for the tm1c and tm1d gel based genotyping 
assays. Tm1d alleles will produce a 174bp product (5’CAS-F1 and 3’LOXP-
R1). 
 
 
 
122 
 
Figure 18 
 
 
 
Figure 18: Summary of the primers utilized for the detection of tm1c, 
tm1b, tm1c, and tm1d  alleles via gel based genotyping strategy 
(adopted from MHC Pon2 HEPD0689_5_E02 Protocol). 
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Figure 19 
 
 
 
 
 
 
 
 
 
 
Figure 19: Representative gel based genotyping results for Tm1a, 
Tm1c, and Tm1d Mice. Representative gel based genotyping results for 
homozygous Tm1a, Tm1c, and Tm1d mice. Six different PCR reactions 
were tested in each mouse for the following alleles, with the expected 
product sizes in parenthesis: (A) Tm1a, (B) tm1c (218 bp), (C) LacZ (108 
bp), (D) FRT (204 bp), (E) NEO (186 bp), and (F) Cardiac Cre (300 bp). 
Furthermore, the tm1a assay will produce the expected product sizes in 
each of the following strains: Tm1a (1 mutant band- 118 bp), Tm1C and D 
(2 bands- 1 mutant band and upper band- ~420 bp). 
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124 
 
Figure 20 
 
 
 
 
Figure 20: Representative immunofluorescence (IF) images of Tm1a, 
Tm1c, and Tm1d. Representative IF images of PON2 and sarcomeric α-
actinin levels in Tm1a, Tm1c, and Tm1d mouse hearts. Anti-PON2 is 
green, anti-sarcomeric α-actinin is red, and nuclei is stained with DAPI as 
blue. Lastly, a merged image is provided combining DAPI, PON2, and α-
actinin.  
 
 
 
 
 
 
 
 
 
 
125 
 
Figure 21 
 
 
Figure 21: Representative image of Cardiac-Cas9 Gel Based 
Genotyping. The presence of the Cardiac-Cas9 allele can be seen via gel-
based genotyping at around 700 bp.  
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Figure 22 
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Figure 22: Results of in vitro mouse PON2 guide RNA T7E1 validation 
experiment. The T7E1 assay was utilized to determine the capacity of the 
PON2 gRNAs to successfully target PON2 via the CRISPR/Cas9 system. 
This is accomplished by T7E1 detecting and cleaving mismatched DNA, 
revealing insertions and deletions that are produced by non-homologous 
end joining activity. Homoduplex (undigested band at ~700bp) and 
heteroduplex (full length band at ~700bp, and digested bands seen at ~500 
bp and ~300 bp) controls worked successfully. HPRT was used as a 
positive control and T7E1 cleavage worked successfully, with the following 
expected results: Full length (647 bp), Fragment 1 (512 bp), and Fragment 
2 (135bp). HPRT negative control worked successfully with full length and 
no digested products. 4 PON2 gRNAs (Guide A, B, C, D) were tested (in 
duplicates) with the expected products as follows: full length (~925 bp), 
Fragment 1 (~654 bp), Fragment 2 (~254 bp). Guide A potentially worked, 
but the digested products are not what was expected; Guide B worked 
successfully; Guide C worked successfully; and Guide D did not appear to 
work, although there is a very faint band at around ~300 bp.  
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Figure 23 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: PON2 Knock down by PON2-gRNA B and C via 
CRISPR/Cas9 system. Protein expression of PON2 in NIH/3T3 cells post 
CRISPR/Cas9 mediated genetic editing. There four groups tested: no 
treatment, negative control, PON2-gRNA B, or PON2-gRNA C.  Guide B 
and C successfully deleted PON2 expression (Duplet at ~45 kDa and 55 
kDa). Vinculin (124 kDa) was also probed on the same blot as a loading 
control.  
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Table 1 
Allele Primer Sequence Results (size) 
Tm1a Pon2-5arm-
WTF 
AGAAAGATGGCTCAGAGGCTA Tm1a Assay:  
WT Band—289bp 
Mutant Band—
118bp 
Pon2-Crit-
WTR 
TGGCTGGGCCTAGATAACTC Tm1c Assay: 
Mutant Band—
118bp 
Upper Band—
~420bp 
5mut-R1 GAACTTCGGAATAGGAACTTCG Post-Flp-- 
Tm1c 5’CAS-F1 AAGGCGCATAACGATACCAC Tm1c band—218 
bp 
3’CAS-R1 CCGCCTACTGCGACTATAGAGA  
Tm1d 5’CAS-F1 AAGGCGCATAACGATACCAC Tm1d band—174 
bp 
3’LOXP-R1 ACTGATGGCGAGCTCAGACC  
Pon2-Crit-
WTR 
TGGCTGGGCCTAGATAACTC  
FRT 5FRT_F 
 
AGGCGCATAACGATACCACGAT 
 
5’FRT band—204 
bp 
 5FRT_R 
 
CCACAACGGGTTCTTCTGTT 
 
 
LacZ LacZ_F 
 
ATCACGACGCGCTGTATC 
 
LacZ band—108 
bp 
 LacZ_R 
 
ACATCGGGCAAATAATATCG 
 
 
Neo Neo-F TTGAACAAGATGGATTGCACGC Neo Band—186 bp 
 Neo-F CCTCGTCCTGCAGTTCATT  
FlpE FlpE_F 
 
CCTAAGGTCCTGGTTCGTCA 
 
FlpE band—229 
bp 
 FplE_R 
 
TTGTTGCTTTTTGCGTCTTG 
 
 
Cardiac 
Cre 
CRE F ATG ACA GAC AGA TCC CTC CTA 
TCT CC 
Cre Positive 
band—300 bp 
 CRE R CTC ATC ACT CGT TGC ATC ATC 
GAC 
Internal Positive 
Control—100bp  
 
Table 1: Primer sequences for all the primers utilized in the gel based 
genotyping strategy, including expected band size (in base pairs). 
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Table 2 
 
 
Table 2: Guide RNA sequences against mouse PON2 used to generate 
CRISPR mediated Cardiac Specific PON2 KO mice.  
 
 
 
 
 
Table 3 
 
Primer 
Sequence Amplicon Generated 
T7E1 PON2 Guide 
A,C,D-F   
GTTCCGTGGTACTGTGTGTAA 
925 bp 
T7E1 PON2 Guide 
A,C,D-R  
CTGTGCATAGGCGTCATTCTA 
T7E1 PON2 Guide B-
F  
CAGCTCCCAGTCACCATTT 
910 bp 
T7E1 PON2 Guide B-
R  
GAATGAGAAGGACAGAGCTACG 
 
Table 3: T7E1 assay primer sequences for PON2 guide RNAs.   
 
Guide RNA Sequence 
Mm.Cas9.PON2.1.AA GAAGGATTCGATTCCGCCAA  CGG 
Mm.Cas9.PON2.1.AB TTTGCACCGGATAAGCCTGG   AGG 
Mm.Cas9.PON2.1.AC GTCGGAGAAGTAGTGGTCAT  TGG 
Mm.Cas9.PON2.1.AD GACATACTTGAACCTACACT   GGG 
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Chapter 5: PON2 Mediated Protection of HSG4112 Against Diet-Induced Obesity 
 
Abbreviations:  
CVD Cardiovascular Disease 
CHD Coronary Heart Disease 
CAD Coronary Artery Disease 
PON Paraoxonase  
3OC12-HSL N-(3-oxododecanoyl)-1-homoserine lactone 
WT Wild-type 
PON2-def PON2-deficient  
LDLR-KO Low density lipoprotein receptor knock-out 
WD Western diet 
HF/HS High fat/high sucrose 
TG Triglyceride 
TC Total Cholesterol 
HDL  High density lipoprotein 
UC Unesterified cholesterol 
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5.1 Introduction 
Coronary Heart Disease (CHD), particularly myocardial infarction, is the leading 
cause of global morbidity and mortality.1, 52, 94 Cardiovascular risk factors for coronary 
heart disease include dyslipidemia, hypertension, diabetes, and obesity.1 Obesity 
accounts for approximately 40% of the risk factors leading to CHD, and over 80% of 
CHD patients are overweight/obese.1 Obesity and its subsequently related array of 
metabolic diseases, including CHD, share various pathophysiological alterations in 
mitochondrial function, oxidative stress, and inflammation.6, 95-97 Consequently, 
discovering a therapeutic agent that can not only reduce obesity, but can also modulate 
these pathophysiological consequences is of paramount importance.  
The Paraoxonase gene family, consisting of PON1, PON2, and PON3, are highly 
conserved in mammals and have a vast role in modulating various metabolic and 
inflammatory diseases, including infection, cardiovascular disease, obesity, and 
cancer.4, 5, 49, 50, 64, 98 Although each PON member has evolved unique substrates and 
mechanisms of action, a conserved mechanism shared amongst all three PON 
enzymes is their ability to hydrolyze lactones, particularly N-acyl-homoserine lactones, 
as well as aromatic esters.40, 99, 100 Our group and others have demonstrated the ability 
that all PONs, particularly PON2, have to hydrolyze and inactivate N-(3-
oxododecanoyl)-1-homoserine lactone (3OC12-HSL), a quoreum-sensing molecule 
produced by gram-negative bacteria thereby reducing bacterial infections in various 
animal models, tissues and cell types.64, 101, 102 Moreover, other underlying mechanisms 
driving PON protection is rooted in their antioxidant capacity and modulation of lipid 
peroxidation.7, 40, 44, 103, 104 In particular, PON2’s protective effects against 
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proatherogenic effects of chronic infection are not only mediated by its ability to 
hydrolyze 3OC12-HSL, but also through protection against mitochondrial ROS 
generation, oxidized phospholipid induced oxidative stress and ER-stress induced 
unfolded protein response.47, 64, 105, 106 Therefore, evaluating lactonase and arylesterase 
activity serves as a valuable method for determining PON activity in experimental 
settings. 
PON2 has been shown in our lab and by others to protect against cardiovascular 
diseases, including atherosclerosis and myocardial ischemia-reperfusion injury, as well 
as cancer and, more recently, diet-induced obesity.5, 6, 48, 50 I and others have 
demonstrated that a key factor mediating this protection is PON2’s capacity to mitigate 
mitochondrial dysfunction and oxidative stress.5, 50 Recently, Dr. Shih, et al., 
demonstrated that PON2 deficient mice (PON2-def) fed a high fat/high (HF/HS) sucrose 
diet developed a significant increase in body weight due to increased fat mass weight, 
as compared to wildtype (WT) controls.6 This phenotype was accompanied by 
mitochondrial dysfunction, with significant decreases in oxygen consumption and 
energy expenditure in PON2-def mice as well as lower oxygen consumption rate in the 
mitochondria derived from white adipose tissue as compared to WT controls.6 
Consequently, the protection afforded by PON2 against diet-induced obesity, makes it a 
valuable candidate to pursue as a mechanism of preventing further cardiovascular 
disease, including myocardial IRI.  
Glaceum, Inc., a Korean biotech company, is interested in treating metabolic 
syndrome and used Glabridin, an isoflavan in licorice roots, as pharmacological target 
to translate into druggable compounds. Isoflavones, including their derivates isoflavoids, 
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are polyphenolic compounds that possess antioxidant properties and are often referred 
to as phytoestrogens, or plant-based compounds that have biological activity through 
the estrogen receptors.107, 108 Glabridin has been shown to have antioxidant, anti-
inflammatory, anti-atherogenic, and anti-bacterial properties, along with protective 
capacities against cancer, atherosclerosis, and neurological diseases.109 Furthermore, 
glabridin was shown to upregulate PON2 expression under hyperglycemia.110 
Subsequently, Glaceum developed and tested over 300 chemical derivates of glabridin, 
and HSG4112 emerged as one of the lead druggable new chemical entities that the 
company discovered. They discovered that the mode of action of their lead compound 
HSG4112, developed for treating metabolic diseases, is via the induction of PON2 
protein. HSG4112 oral administration (for 6 weeks) resulted in 38% reduction of food 
intake, a 62% increase in energy expenditure, and a 26% drop in weight in mice a diet-
induced obesity model in mice (data not published). Additionally, HSG4112 treatment 
resulted in a significant increase in PON2 expression (Supplemental Figure 6) and the 
proposed mode of action by Glaceum for HSG4112 was determined to be a PON2 
dependent modulation of mitochondrial dysfunction (data not published). Glaceum 
reached out to our lab and requested to collaborate to further explore the role of 
HSG4112 against diet-induced obesity using our PON2-def mouse model to evaluate 
the potentially causal role that PON2 plays as a mode of action of HSG4112. Our 
laboratory signed an MTA with Glaceum, Inc. and obtained HSG4112. My hypothesis is 
that HSG4112 will be protective against diet-induced obesity by reducing body weight 
and fat mass, while increasing lean mass, in a PON2 dependent manner.  
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With this compound in hand, I performed a series of experiments to test my 
hypothesis: 1) Baseline assessment of Chow diet ± HSG4112 on three mouse models: 
WT, PON1-KO, and PON2-def. 2) Assessment of HF/HS ± HSG4112 on WT and 
PON2-def mice. 3) Rescue capacity of HSG4112 against diet-induced obesity on WT 
and PON2-def mice. 4) Assessment of Chow diet ± HSG4112 and Western Diet ± 
HSG4112 on a mouse LDLR-KO, or hyperlipidemic, background. 
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5.2 Materials and Methods 
5.2.1 Mice and Diets 
All mouse breeding and experimental protocols were approved by the UCLA 
Animal Research Committee (ARC), in accordance with PHS guidelines. WT and 
PON2-def mice were generated as a result of a PON2 heterozygous intercross. PON1-
KO mice were also generated from a heterozygous intercross. Lastly, the LDLR-KO 
mice were originally purchased from Jackson Laboratories and obtained from the 
Department of Laboratory and Animal Medicine at David Geffen School of Medicine at 
UCLA. All the mice used are on a C57BL/6J background. Both male and female mice 
were utilized for these experiments and ranged from 8 to 12 weeks of age, which are 
further specified in each experimental design as noted in the respective figure legends. 
Based on the experimental design, mice were fed a standard mouse chow diet (Ralston 
Purina), a western diet (WD; Teklad, Harlan, catalog# TD88137), and/or a high fat/high 
sucrose diet (HF/HS; Research Labs, catalog# D12266B), with and without HSG4112 
(Glaceum Inc.), which was mixed with the diet at a dose of 100mg/kg. All mice were 
weighed both prior to start of the experiment and every subsequent week until 
termination. Lastly, mice were fasted overnight prior to blood and tissue collection.  
5.2.2 Plasma Lipids and Glucose Measurement  
Plasma lipids, including triglycerides, total cholesterol, high density lipoprotein 
(HDL), and unesterified cholesterol, as well as glucose levels were determined using 
enzymatic colorimetric assays,6 with final concentrations expressed as mg/dL.  
5.2.3 Body Composition Measurement  
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Body composition, specifically total body fat and lean mass was determined 
using quantitative nuclear magnetic resonance (NMR) via the Bruker MiniSpec utilizing 
software from Echo Medical Systems. The percent of total body fat and lean (muscle) 
mass was determined by dividing the total body fat/lean mass by total body weight, 
taken just prior to NMR, and then multiplying by 100.  
5.2.4 Immunoblotting  
50 micrograms of protein from plasma and liver lysates were loaded on 4–20% 
Mini-PROTEAN TGX Stain-Free protein gels (Bio-Rad, Hercules, CA, USA) and 
transferred to nitrocellulose membranes. The membranes were blocked for 1 h at room 
temperature in Tris-buffered Saline with 0.1% Tween 20 (TBST) containing 5% (w/v) 
milk. The following primary antibodies were used at the specified dilutions: PON1 
(catalog# MAB4926, R&D Systems) at 1:1000, PON2 (Catalog# A00816, GenScript), 
PON3 (catalog# AF4345, R&D Systems) at 1:1000, Vinculin (catalog# V9131, Sigma-
Aldrich) at 1:5,000. Primary antibodies were diluted in TBST containing 5% milk at 4oC 
overnight, followed by incubation with appropriate secondary antibody (1:5,000 dilution) 
coupled to HRP for 1 hour. Protein was detected using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore Sigma, USA). Western blot images were 
quantified using the ImageJ software. 
5.2.5 Lactonase and Arylesterase Assays 
Plasma and liver homogenates (20mg) were utilized for the lactonase and 
arylesterase assays. The protocol for the assays were as follows:  
Lactonase Assay111 
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Stock solutions of 100 mM dihydrocumarin (Catalog# 104809-5G, Sigma) in 
DMSO (can keep for up to 2 weeks at 4°C) were prepared fresh. The stock was diluted 
to 2 mM with reaction buffer (freshly prepared; 50mM Tris HCl, pH 7.5, 1 mM CaCl2), 
and a final concentration of 1 mM is used. Dilute plasma 1:10 with reaction buffer 
(dilution factor depends the activity of PON1). Nondiluted HDL was used. 3 µl of the 
diluted plasma or 10-15 µl of mouse HDL was added to the wells of a UV microplate. 
Reaction buffer was added to complete the volume to 100 µl. Also, self hydrolysis of 
dihydrocoumarin was measured. 100 µl of 2 mM dihydrocumarin was added. 
Absorbance at 270 nm was read for 10 minutes every 15 seconds. The Mean V 
mOD/minute values were acquired. Following conditions were utilized for the 
determination of the final concentration : 1 unit = 1 µmol of dihydrocumarin hydrolyzed 
per minute per 1 ml; extinction coefficient: E270 = 1295/M/cm; Calculation: - [(Mean V of 
sample - Mean V of self hydrolysis) × 5 × dilution factor]/700 = units/ml. Serum 
lactonase activity toward dihydrocoumarin in healthy subjects is in the range of 13–20 
units/ml. 
Arylesterase Assay112 
Assay Buffer (9.0 mM Tris.HCl, pH 8.0, 0.9 mM CaCl2) and Substrate Solution 
(25 µl of phenyl acetate (catalog# P-2396, Sigma) dissolved in 50 ml of assay buffer) 
were prepared fresh before assay. Plasma was diluted 1:50 (10 µl plasma + 490 µl 
assay buffer), 20 µl were aliquoted into each well of the 96-well flat bottom UV plate 
(catalog#: 3635, Costar), with duplicated determinations made for each sample. The 
plate reader (Molecular Devices, model:Spectra Max 190) was configured with the 
following settings: Function: Kinetics, Wavelength: 270 nm, Interval time: 15 seconds, 
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Total Time: 2 minutes. Using a multichannel pipet, 180 µl of substrate solution was 
added into each well. The plate was then quickly added to the plate reader and readings 
began right away. The machine computed the rate as follows: v( in mO.D./min). V was 
multiplied by 2.5 to obtain O.D./min/ml of plasma. The following calculation was utilized 
for final concentration: L = path length of the spectrometer (cm), Molar E 270 for phenol 
(product) = 1310, 1 mole/liter = 1310 A270 in a spectrometer of 1 cm path length. 
Therefore, Arylesterase activity = 2.5 *v *0.7633/L= v * 1.9083/L (Units/ml of plasma). 
5.2.6 Statistical Analysis 
Student's t-tests were carried out between all studies with two groups. Data from 
experiments with two or more groups were compared using a one-way ANOVA model. 
After a significant overall group effect was established, Tukey's pairwise comparisons 
were carried out to determine specific group to group differences. Experiments were 
repeated two to three time to ensure that the results were consistent and reproducible. 
All data are represented as mean ± SEM. A p-value<.05 was considered statistically 
significant. 
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5.3 Results 
5.3.1 Role of HSG4112 in modulating expression and activity of Paraoxonases. 
In order to elucidate the potential role that HSG4112 might play in modulating 
Paraoxonase expression and activity, I performed a pilot experiment in which Control 
(WT, C57BL/6J), PON1-KO, and PON2-def mice (n=8/group) were fed Chow ± 
HSG4112 for 2 weeks (Figure 24A). Subsequently, using both plasma and liver 
acquired before and after HSG4112 treatment, I evaluated the protein expression of 
PON1, PON2, and PON3 as well as the lactonase, arylesterase, and paraoxonase 
activities. Paraoxonase activity in the plasma post-HSG4112 treatment is significantly 
reduced in the control and PON2-def groups, while it is significantly increased in the 
PON1-KO group, when compared to pre-HSG4112 treatment (Figure 24B). In addition, 
arylesterase and lactonase activity was significantly increased in the plasma post-
HSG4112 across all three groups (Control, PON1-KO, and PON2-def), when compared 
to pre-HSG4112 treatment (Figure 24B). Furthermore, when evaluating arylesterase 
and lactonase activity the liver post-HSG4112, I observed no significant differences in 
the control group, while there is a significant increase in activity in both assays in the 
PON1-KO and PON2-def groups, when compared to pre-HSG4112 treatment (Figure 
24C).  
Next, when looking at the protein expression of PON1, PON2, and PON3 in the 
plasma post-HSG4112 treatment, I observed that PON1 is significantly increased in the 
Control, WT group and PON2-def group, with the PON2-def group demonstrating a 
significant increase in PON3 expression as well, when compared to chow fed controls 
(Figure 24D). Lastly, PON1 is significantly increased in livers of PON2-def mice, along 
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with PON3 in PON1-KO and PON2-def mice, treated with HSG4112 versus chow 
controls (Figure 24E).  
HSG4112’s ability to increase PON enzymatic activity (lactonase and 
arylesterase) and induce PON protein expression in the plasma and liver of WT, PON1-
KO and PON2-def mice under baseline, untreated conditions supports the role that 
HSG4112 functions, at least in part, through the PON gene family. Additionally, as 
noted earlier, Glaceum observed a significant induction of PON2 expression in a diet-
induced obesity model (Supplementary Figure 6), and proposed PON2 as a mode of 
action for HSG4112. Therefore, I sought to determine whether the protective properties 
of HSG4112 are, at least in part, mediated by PON2.  
5.3.2 Role of PON2 in modulating the protective effects of HSG4112  
To assess the role that PON2 plays in potentially modulating the protective 
effects of HSG4112, I utilized PON2-def mice and WT mice as controls (n=10/group). 
Both male and female mice were used and fed a WD (HF/HS) diet ± HSG4112 for 3 
weeks (Figure 25A). Changes in weight (in grams) was determined in WT and PON2-
def mice two weeks after being on HF/HS ± HSG4112, with both male and female 
groups demonstrating a significant decrease in weight with the HSG4112 treatment, 
when compared to HF/HS controls (Figure 25B). Nevertheless, the PON2-def group fed 
the HF/HS diet with HSG4112 had a borderline significant (p=0.054) reduction in the 
magnitude of weight change compared to the female, WT group fed the same diet. Fat 
and muscle mass were also determined via NMR for all mice groups and, as noted 
above, percent fat and muscle (lean) mass is calculated as fat/muscle mass over total 
body weight x 100. Percent fat was significantly reduced in both male and female, WT 
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mice fed HF/HS + HSG4112, when compared to just HF/HS diet alone (Figure 25C). 
Furthermore, there were no significant differences in percent fat between either male or 
female, PON2-def diet groups (Figure 25C). Although percent muscle slightly increases 
in the HSG4112 treated groups, it is only significantly increased in the female, WT mice 
compared to just WT, HF/HS controls (Figure 25D).  
Next, I evaluated lactonase and arylesterase activity in the plasma and liver of 
these mice. Lactonase activity was only significantly increased in the plasma for the 
female, WT group fed HF/HS + HSG4112, compared to control (Figure 25E). Moreover, 
arylesterase activity is significantly increased in the female, PON2-def group on a 
HF/HS + HSG4112 diet, compared to controls (Figure 25E). Of note, as expected, both 
lactonase and arylesterase is significantly reduced in the HF/HS fed PON2-def group 
versus WT controls. There were no significant differences in lactonase activity in the 
liver between the WT and PON2-def groups fed HF/HS ± HSG4112, except for a 
significant decrease in the PON2-def fed HF/HS diet versus its WT control (Figure 25F). 
However, there was a significant decrease in arlyesterase activity in the liver of the WT 
mice fed a HF/HS + HSG4112, when compared to control (Figure 25F). In addition, 
arylesterase activity in the liver is significantly decreased in the PON2-def group fed 
HF/HS diet versus its WT control (Figure 25F).  
Plasma lipid panel (triglycerides, total cholesterol, HDL, and unesterified 
cholesterol) and glucose levels were evaluated in both male and female, WT and 
PON2-def mice fed HF/HS ± HSG4112 and WD ± HSG4112 diet (Table 4). Triglyceride 
levels were significantly elevated in the male, WT group on the HF/HS + HGS4112 diet 
versus WT, HF/HS controls (Table 4). However, there is a significant decrease in the 
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triglycerides in the female, PON2-def group fed a HF/HS + HSG4112, when compared 
to HF/HS fed PON2-def controls (Table 4). Also, there is significant decrease in HDL in 
the female, WT mice on a HF/HS + HSG4112 diet versus HF/HS, WT controls (Table 
4). Lastly, there is a significant decrease in glucose levels in the male, WT and male, 
PON2-def mice on a HF/HS + HSG4112 versus their respective controls (Table 4). 
Nevertheless, this significant decrease in glucose levels is absent in the female WT, 
PON2-def groups. (Table 4).  
PON2 deficiency significantly limited the protective effects of HSG4112. Although 
there was a significant reduction in body weight in both WT and PON2-def mice fed the 
HF/HS diet with HSG4112, the significant reduction of fat mass and lean observed in 
the WT, HSG4112 treated groups (both male and female) is lost in the PON2-def 
groups fed HSG4112. Furthermore, the significantly increased lactonase and 
arylesterase activity observed in the WT groups treated with HSG4112 is absent in the 
PON2-def groups fed HSG4112. Lastly, the significant reduction of glucose levels in 
both male, WT and PON2-def groups treated with HSG4112, is lost in the female, 
PON2-def group treated with HSG4112.  
My observation that the protective effects of HSG4112 is reduced in PON2-def 
mice (specifically females) led me to conduct another experiment in which I would test 
the potential for HSG4112 to rescue the diet-induced obesity phenotype, in both WT 
and PON2-def mice fed an obesifying diet.  
5.3.3 Limited capacity of HSG4112 to rescue obesity phenotype in PON2-def mice 
To investigate the potential role of HSG4112 in rescuing the effect of diet-
induced obesity, I performed a study which consisted of WT and PON2-def mice 
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(n=10/group) that were fed a HF/HS (WD) diet for three weeks, after which they were 
placed on a HF/HS diet + HSG4112 for another three weeks (Figure 26A). Changes in 
weight (in grams) were then assessed post-week 3 to assess the changes due to 
western diet alone, as well as at the end of week 6 to assess a potential rescue effect of 
HSG4112 on the changes due to the obesifying diet (Figure 26B). There was a 
significant weight increase in the male, WT mice versus the male, PON2-def mice after 
three weeks of HF/HS diet (Figure 26B). This increase in body weight was significantly 
reduced by HSG4112 treatment in the male, WT mice, while not changing significantly 
in the male, PON2-def group (Figure 26B). Furthermore, there was a significant 
difference in the change in weight between the male, WT and PON2-def groups after 3 
weeks of HSG4112 treatment, with the male, WT group having a greater change in 
weight versus the male, PON2-def mice (Figure 26B). On the other hand, the female, 
PON2-def mice significantly gained more weight when on the HF/HS diet for three 
weeks, when compared to the female, WT group. Nevertheless, treatment with 
HSG4112 for three weeks significantly reduced the change in weight, causing the mice 
to actually lose some weight (compared to week 3 weights), in both the WT and PON2-
def groups (Figure 26B).  
Fat and muscle (lean) mass was determined via NMR for all groups and percent 
fat/muscle mass is quantified as the fat/muscle mass (g) over total body weight (g) at 
the given time point x 100. Male, WT mice have a significant increase in percent fat at 
the end of 3 weeks of HF/HS diet, which is not significantly reduced by HSG4112 
treatment for another three weeks (Figure 26C). Male, PON2-def mice do not 
significantly increase in fat mass after 3 weeks of HF/HS diet, and HSG4112 does not 
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appear to have a significant effect in modulating fat mass after three weeks as well 
(Figure 26C). The male, WT mice have a significantly elevated percent of fat after both 
week 3 and week 6, when compared to the male, PON2-def group. Female, PON2-def 
mice significantly increase their percentage of fat mass after three weeks of HF/HS diet, 
but three weeks of HSG4112 treatment does not significantly rescue that phenotype 
(Figure 26C). Although the female, WT mice are initially resistant to any changes in fat 
mass during the three weeks of HF/HS feeding, HSG4112 significantly reduces their fat 
mass after three weeks of treatment (Figure 26C). Furthermore, there is a significant 
increase in fat mass between female, PON2-def mice compared to the female, WT mice 
at both week 3 and week 6 of the study (Figure 26C). Muscle mass was significantly 
reduced in the male, WT mice after three weeks of HF/HS diet, but does not 
significantly change after three weeks of HSG4112 treatment, although it does not drop 
further (Figure 26D). Similarly, muscle mass significantly drops in both the female, WT 
and PON2-def female groups after three weeks of HF/HS diet. In addition, HSG4112 
treatment for three weeks fails to improve muscle mass for either female, WT or PON2-
def mice (Figure 26D). Nevertheless, at the end of week 6, female, PON2-def mice 
have a significantly decreased muscle mass when compared to female, WT controls.  
Lastly, food consumption was measured over the course of the study (Figure 
26E). Food consumption is reduced over time for both male and female WT groups. 
90% of HF/HS diet is consumed by both male and female WT mice at the end of week. 
However, HSG4112 treatment appears to reduce food consumption down to about 82% 
for males and 75% for females by the end of week 6 of the study. Similarly, both male 
and female PON2-def mice consume about 90% of the HF/HS diet by the end of week 
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3. However, there is a more pronounced reduction in food consumption in the female 
mice (about 55%) versus males (about 80%), by the end of three weeks of HSG4112 
treatment.  
 HSG4112 treatment after diet-induced obesity largely fails to rescue the negative 
phenotypes in PON2-def groups (particularly females), which includes an inability of 
HSG4112 treatment to rescue increases in fat mass and decreases in lean mass. 
Nevertheless, HSG4112 treatment was still successful in significantly reducing the body 
weight of both WT and PON2-def mice after three weeks of obesifying diet. Given the 
limited capacity of HSG4112 to protect against diet-induced obesity in PON2-def mice, I 
sought to investigate the protective properties of HSG4112 against diet-induced obesity 
in hyperlipidemic mice.  
5.3.4 HSG4112 Protection Against Diet-Induced Obesity in Hyperlipidemic Mice 
LDLR-KO mice were utilized to test the efficacy of HSG4112 against 
hyperlipidemia. In this study, male and female LDLR-KO mice (n=10 per group) were 
fed a Chow diet or WD, both with and without HSG4112 for three weeks (Figure 27A). 
Changes in weights (in grams) were determined at the end of the study and compared 
to the initial weights of the mice before the study began. There were no changes 
observed in both males and females fed the Chow ± HSG4112. Nevertheless, 
HSG4112 was able to significantly reduce the weight of both male and female mice fed 
WD with HSG4112, when compared to just WD alone (Figure 27B). Next, using NMR, I 
determined the changes in fat and muscle (lean) mass, which I represented as a 
percent change (fat/muscle mass over total body weight x 100). Similar to what I 
observed in body weight, there were no significant changes in % fat mass in both male 
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and female mice fed the Chow ± HSG4112 diet (Figure 27C). However, there is a 
significant drop in % fat mass, about 50% (from ~20% to ~10%) in the male and female 
fed a WD with HSG4112 versus WD controls (Figure 27C). In addition, the percent 
muscle mass was significantly increased in the WD + HSG4112 group versus the WD 
controls, with no change observed in the Chow ± HSG4112 groups (Figure 27D).  
Lactonase and arylesterase activities were evaluated in the plasma and livers 
from this study. Although there were no significant differences in the arylesterase 
activity between any of the groups, I observed a significant drop in the lactonase activity 
in the female WD mice versus chow controls (Figure 27E). Yet, there is a strong trend 
(p=0.056) for an increase in lactonase activity in females on a WD with HSG4112 
versus WD controls (Figure 27E). On the other hand, the lactonase and arylesterase 
activity in the liver are significantly decreased between both the Chow + HSG4112 and 
WD + HSG4112 groups, compared to their respective controls (Figure 27F).  
Lastly, plasma lipid panel (triglycerides, total cholesterol, HDL, and unesterified 
cholesterol) and glucose levels were evaluated in both male and female, Chow ± 
HSG4112 and WD ± HSG4112 (Table 5). Triglyceride levels were significantly elevated 
in both the male and female Chow + HGS4112 versus chow controls, while no 
significant difference is observed in either male or female WD ± HSG4112 groups 
(Table 5). There is significant decrease in the total cholesterol in the male WD + 
HSG4112 versus WD controls (Table 5). Lastly, there is a trend (p=0.09) in decreased 
glucose levels in the male, chow + HSG4112 (versus chow), while a significant 
decrease in glucose is observed in the female, chow + HSG4112 (versus chow) and a 
strong trend (p=0.06) in the female, WD + HSG4112 group (versus WD) (Table 5).  
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Under a hyperlipidemic, LDLR-KO background, HSG4112 significantly reduced 
body weight and fat mass, while increased lean mass in male and female mice fed a 
WD and not in chow. Furthermore, there were no significant enhancements of PON 
enzymatic activity with HSG4112 treatment. On the contrary, HSG4112 treatment 
significantly reduced lactonase and arylesterase activity in the plasma of both chow and 
WD fed mice. Also, HSG4112 treatment affected plasma lipid and glucose level, 
significantly increasing triglyceride in the chow fed group, decreasing total cholesterol in 
males fed WD, and decreasing glucose levels in females fed WD.  
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5.4 Discussion 
Diet-induced obesity is major risk factor for cardiovascular disease, specifically 
coronary heart disease. In this study, I investigated the potential role that a novel 
therapeutic, HSG4112, could play in mitigating diet-induced obesity via the 
Paraoxonase gene family, specifically PON2. I utilized four different experimental 
models to undertake this project.  
In order to assess the baseline function of HSG4112 and the role that the 
Paraoxonase gene family, including PON1, PON2, and PON3, could play in modulating 
its protective effects, I administered Chow ± HSG4112 (100 mg/kg) to WT (C57BL/6J), 
PON1-KO, and PON2-def mice for 2 weeks. HSG4112 did not have a pronounced 
effect on weight (data not shown), however it did have a significant effect on PON 
meditated activity, namely lactonase and arylesterase. HSG4112 enhances the 
lactonase and arylesterase activity in the plasma in all three experimental groups 
(Figure 24B), as well as in the PON1-KO and PON2-KO groups in the liver (Figure 
24C). Furthermore, HSG4112 induces the protein expression of PON1 in the plasma of 
WT mice and plasma and liver of PON2-def mice, while also inducing PON3 in the livers 
of both PON1-KO and PON2-def mice (Figure 24D,E). These data support the theory 
that HSG4112’s mechanism of action is potentially via the PON gene family, more 
specifically acting as a mechanism to rescue the loss of function observed in mice 
genetically deficient of a member of the PON gene family.  
A recent study was published by Dr. Shih et al. demonstrating that PON2 
deficiency in mice, specifically females not males, led to diet-induced obesity, when the 
mice were fed a high fat, high sucrose diet. Furthermore, these PON2-def mice 
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exhibited significantly increased fat mass weight, impaired glucose tolerance, and 
mitochondrial dysfunction (decreased oxygen consumption and energy expenditure) 
when fed the obesifying diet, as compared to WT controls.6 In addition, PON2-def mice 
have a greater susceptibility to develop atherosclerosis5 and develop larger infarcts 
when subjected to acute myocardial ischemia-reperfusion injury.50 Furthermore, given 
the potential of HSG4112 to induce PON2 expression in a diet-induced obesity model, I 
explored the role that PON2 might be playing as a mode of action for HSG4112 by 
conducting experiments using PON2-def mice on an obesifying diet.  
Male and female, WT and PON2-def mice (n=5/group) were fed a high fat, high 
sucrose diet ± HSG4112 for three weeks (Figure 25A). Male, PON2-def mice did not 
significantly gain weight after being fed an obesifying diet, while the female, PON2-def 
group did (Figure 25B). This result mirrors what Dr. Shih observed in her studies and 
suggests a sex specific effect that PON2 deficiency plays in the development of obesity.  
HSG4112 significantly reduces the body weight of both male and female, WT and 
PON2-def groups, compared to controls (Figure 25B). While there is not a significant 
difference in the change in weight between the male, WT and PON2-def mice on the 
HF/HS + HSG4112 diet, there is a significantly reduced capacity of the drug to decrease 
the body weight of the female, PON2-def group when compared to the WT, drug treated 
group (Figure 25B). This indicates that although HSG4112 appears to have a protective 
effect in reducing body weight, that capacity is limited when PON2 is deficient, 
suggesting that PON2 might play a role in HSG4112’s mechanism of action. 
Furthermore, HSG4112 significantly reduces the fat mass (both male and female) and 
increases muscle mass (male) in the WT group, but that protective effect is absent in 
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the PON2-def group (Figure 25C-D). Additionally, lactonase activity in the plasma of the 
PON2-def mice was not significantly changed by HSG4112 treatment (Figure 25E), a 
shift from its enhancing effect seen under baseline, chow fed conditions, further 
supporting the theory that HSG4112’s protective effect is diminished when encountering 
an external stressor, in this case an obesifying diet and PON2 deficiency. Moreover, 
HSG4112 treatment only significantly reduces plasma glucose levels in the WT (male 
and female) groups, it does not do so in the PON2-def groups (Table 4). These data 
strongly suggest that PON2 could play a significant role in modulating HSG4112 
function.  
In order to test whether HSG4112 has potential to rescue the diet-induced 
obesity phenotype, I conducted a final experiment whereby WT and PON2-def mice 
were fed HF/HS diet for three weeks, followed by a HF/HS diet with HSG4112 for 
another three weeks. Body weights were significantly reduced with HSG4112 treatment, 
for both WT and PON2-def groups (Figure 26B).  Fat mass is significantly increased by 
HF/HS diet after 3 weeks of feeding in both WT and PON2-def groups. Nevertheless, fat 
mass is only reduced by HSG4112 in the female, WT group, with the female, PON2-def 
group maintaining significantly higher fat mass content than their WT controls (Figure 
26C). Also, HSG4112 is unable to rescue the loss of muscle mass in both WT and 
PON2-def groups (Figure 26D). Lastly, HSG4112 treatment strongly reduces food 
consumption in the PON2-def group, particularly in the females (Figure 26E), which can 
serve as one explanation for the pronounced loss of body weight in the PON2-def 
groups. Yet it is worth noting that although the PON2-def mice, specifically the females, 
on the diet with HSG4112 ate dramatically less than their WT controls, they still 
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maintain a high fat mass indicating that: a) their lack of food consumption has no 
bearing on their capacity to develop obesity, in terms of fat mass content and b) 
HSG4112 is confirmed to have no capacity to reduce their fat mass content, which it 
consistently does in its WT control group (Figure 24C, 25C). Nevertheless, it is 
important to determine whether the mice are merely not eating the food due to their own 
desire or whether HSG4112 is suppressing their appetite, which measuring plasma 
leptin and insulin levels can help delineate. To further elucidate the protective role that 
HSG4112 plays in modulating diet-induced obesity, I used a hyperlipidemic, LDLR-KO, 
mouse model. 
LDLR-KO mice were fed either a Chow ± HSG4112 or an obesifying western diet 
(WD) ± HSG4112 for three weeks (Figure 25A). HSG4112 only significantly reduces the 
body weights and fat mass, while increasing muscle mass in both male and female, 
LDLR-KO mice on the western diet; while unaltering the body weights, fat mass, or 
muscle mass of LDLR-KO mice fed a chow diet (Figure 25B-D). This suggests that 
although someone might be predisposed to obesity, HSG4112’s protective effects are 
only observed when the body is faced with an external stressor, namely an obesifying 
diet. In this study, lactonase and arylesterase activity was not enhanced in the plasma 
of any group (Figure 25E). Moreover, HSG4112 treatment in both male and female, 
LDLR-KO mice fed chow or WD led to a significant decrease in both lactonase and 
arylesterase activity. Therefore, it might be noted that genetic predisposition for 
hyperlipidemia might negatively interfere with the pathway by which HSG4112 acts to 
modulate various innate paraoxonase activities. Furthermore, this paradoxical 
observation extends to HSG4112’s role in modulating plasma lipids. More specifically, 
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HSG4112 treatment increases triglycerides in all groups, but only significantly in the 
male and female groups fed chow + HSG4112 (Table 1). On the other hand, HSG4112 
treatment decreases plasma glucose levels in all groups, while only significantly in the 
female chow + HSG4112 group and trending significantly (p=0.06) in the female WD + 
HSG4112. These data also seem to point to a possible gender specific role for 
HSG4112.  
It is worth noting the gender specificity that PON2 deficiency has in both inducing 
obesity through a HF/HS diet (previously reported) and the amelioration of HSG4112 
protection.6 One possible explanation could be in the differential expression of PON2 
between male and female mice, with WT, female mice expressing higher PON2 levels 
in all tissues.113 In fact, estrogen has been shown to induce PON2 expression, with 
estradiol transcriptionally activating PON2 via activation of estrogen receptor-α.114 This 
modulation was further observed in female mice that received an ovariectomy, in which 
PON2 levels were significantly reduced the striatum, cerebral cortex and liver to levels 
observed in males.114 Also, glabridin and derivates has been shown to bind to estrogen 
receptor and have estrogen-like activities, such as having inhibitory effects on the 
growth of breast cancer.115 Therefore, HSG4112’s protective effect could also be acting 
by way of estrogen agonism; thus potentially having more robust effects on females, 
although that still needs to be determined. Taken together, the increased expression of 
PON2 in female, WT mice (and thus more pronounced loss in PON2-def mice) coupled 
with the potential for the involvement of estrogen agonism by HSG4112, could serve as 
potential explanation for increased susceptibility of female, PON2-def mice to diet-
induced obesity and the corresponding loss of HSG4112’s protective effects.  
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The protective capacity of HSG4112 on diet-induced obesity, which is 
significantly reduced in PON2 deficiency, strongly suggests the role that PON2 plays as 
a mode of action for the drug. Recent studies by Glaceum have demonstrated that 
HSG4112 significantly reduces mitochondrial ROS and increases ATP production 
(unpublished data). This overlaps with PON2’s protective capacity of reducing 
mitochondrial ROS and increasing ATP, among other protective phenotypes, and 
supports the connection of PON2 in modulating HSG4112’s therapeutic effects.5, 50 
Consequently, HSG4112’s antioxidant properties in the mitochondria could further 
extend to modulating lipid peroxidation, leading me to hypothesize that HSG4112 will 
reduce lipid peroxidation, particularly in the mitochondria. Therefore, evaluating the 
ability of HSG4112 to modulate systemic and mitochondrial lipid peroxidation, 
specifically eicosanoid and prostanoid production, will serve as an important mechanism 
of action to explore; especially given PON2’s ability to modulate mitochondrial lipid 
peroxidation.  
 
 
 
 
 
 
 
 
 
155 
 
5.5  Conclusions 
• HSG4112 modulates PON activity under baseline (chow diet) conditions, 
significantly enhancing lactonase and arylesterase activity in the plasma and 
livers of WT, PON1-KO, and PON2-def mice, while also enhancing PON1 and 
PON3 protein expression in these mice as well (compared to chow fed controls). 
• PON2 deficiency significantly reduces the protective capacity of HSG4112. 
Although there is a reduction in body weight in both WT and PON2-def mice fed 
a HF/HS diet with HSG4112, the difference in body weight loss in the PON2-def 
(female) mice is significantly reduced compared to the WT controls. Moreover, 
HSG4112 treatment fails to reduce fat mass, increase muscle mass, enhance 
lactonase activity or reduce plasma glucose levels.  
•  HSG4112 treatment has a limited capacity to rescue the obesifying effect of 
three weeks of HF/HS diet in both WT and PON2-def mice. Although HSG4112 
treatment significantly reduced the body weight of both female WT and PON2-def 
groups treated with HSG4112 after three weeks of obesifying diet, only the 
female, WT group had a significant reduction of fat mass. This further supports 
the role that PON2 plays as a mode of action for HSG4112 protection. 
• HSG4112 has protective effects against hyperlipidemic (LDLR-KO), western diet 
fed mice, significantly reducing the body weight and fat mass, while increasing 
lean mass in both male and female groups. Furthermore, HSG4112’s capacity to 
reduce plasma glucose levels in these mice was only observed in the female 
mice.  
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• Of note, HSG4112’s protective effect on body weight and fat/muscle mass was 
only observed in the LDLR-KO mice fed a high fat, western diet and not a chow 
diet. This suggests that an external stressor (i.e. diet) is needed to trigger the 
effects of HSG4112, regardless of genetic predisposition to hyperlipidemia.  
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Figure 24A 
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Figure 24B 
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Figure 24C 
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Figure 24D 
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Figure 24E 
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Figure 24: Role of HSG4112 in modulating expression and activity of 
Paraoxonases. (A) Three mice stains were utilized for this study, WT 
(C57BL/6J), PON1-KO, and PON2-def. Both male and females, between 8-
10 weeks of age, were used with 8 mice per group for the HSG4112 
treated mice, whereas the respective age/sex matched controls were 3-4 
mice per group. The mice were weighed and bled prior to the start of the 
experiment. The mice were left on a standard chow diet for 2 weeks, 
followed by another two weeks of chow ± HSG4112. At the end of 4th week, 
the experiment was terminated. Paraoxonase, Arylesterase, and Lactonase 
assays were performed on the plasma (B) and livers (C) from control, 
PON1-KO, and PON2-def mice. Of note, the results from the pre-HSG4112 
group are from pre-bleeds collected prior to the start of the experiment, 
while the post-HSG4112 group are from the plasma collected during the 
termination of the experiment. (D) PON1 expression (n=4/group) was 
evaluated in the plasma of WT and PON2-def mice via western blot 
analysis, normalized to transferrin, and quantified as a ratio of PON1 to 
transferrin. (E) PON1 and PON3 expression (n=4/group) were evaluated in 
livers of PON1-KO and PON2-def mice fed Chow ± HSG4112, via western 
blot analysis, normalized to vinculin, and quantified as a ratio of 
PON1/PON3 to vinculin. 1 unit=µmole of dihydrocumarin (for lactonase) or 
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phenyl acetate (for arylesterase) hydrolyzed per minute. The data is 
represented as Mean ± SEM and statistically significant data is noted as 
*p<0.05,**p<0.01, ***p<0.001, ****p<0.0001. 
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Figure 25A 
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Figure 25C 
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Figure 25D 
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Figure 25E 
 
W
T
W
T 
+ 
D
PO
N
2-
de
f
PO
N
2-
de
f +
 D
0
10
20
30
40
50
Lactonase- Plasma
U
n
it
s
/m
L
 o
f 
P
la
s
m
a
*(for females)
✱✱✱
                                
W
T
W
T 
+ 
D
PO
N
2-
de
f
PO
N
2-
de
f +
 D
0
100
200
300
400
Arylesterase- Plasma
U
n
it
s
/m
L
 o
f 
P
la
s
m
a
 
✱✱✱✱
✱(for females)
 
 
 
 
 
168 
 
Figure 25F        
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Figure 25: Role of PON2 in modulating the protective effects of 
HSG4112. (A) WT (C57BL/6J) and PON2-def mice were utilized to 
investigate the role of PON2 in modulating the protective effects of 
HSG4112 against diet-induced obesity. Mice were fed High Fat/High 
Sucrose (HF/HS) with and without HSG4112 for 3 weeks. Dosing of 
HSG4112 was at 100mg/kg. Both male and female mice, between 9-20 
weeks of age, with 5 mice per group were used for this study. The mice 
were weighed prior to the start of the experiment. At the end of third week 
of feeding, the experiment was terminated. (B) Changes in weight (grams) 
were determined between the weight of the mice before the start of the 
experiment and weights collected at the end of 2 weeks of diet. (C) Fat 
mass changes were assessed and quantified as percentage of final fat 
mass (grams) over total body weight (grams) x 100. (D) Muscle (lean) 
mass were assessed and quantified as percentage of final muscle mass 
(grams) over total body weight (grams) x 100. Arylesterase and lactonase 
activities were assessed in the terminal collections of plasma (E) and livers 
(F). 1 unit=µmole of dihydrocumarin (for lactonase) or phenyl acetate (for 
arylesterase) hydrolyzed per minute. The data is represented as Mean ± 
SEM and statistically significant data is noted as *p<0.05,**p<0.01, 
***p<0.001, ****p<0.0001. 
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Figure 26A 
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Figure 26B 
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Figure 26C 
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Figure 26D 
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Figure 26E 
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Figure 26: Limited capacity of HSG4112 to rescue obesity phenotype 
in PON2-def mice. (A) WT (C57BL/6J) and PON2-def mice were utilized to 
investigate the rescue potential of HSG4112 against diet-induced obesity, 
while concurrently determining the role PON2 in modulating the protective 
effects of HSG4112. Both male and female mice, between 8 - 10 weeks of 
age, with 5 mice per group were used for the study. One week prior to the 
start of the experiment, mice were weighed, bled for plasma, and NMR was 
performed to measure fat and lean mass. After one week of recovery, mice 
were fed HF/HS for 3 weeks. Three days prior to the third week of feeding, 
the mice were weighed, bled for plasma, and NMR was performed to 
measure fat and lean mass. Subsequently, the mice were given 3 days to 
recover (still on HF/HS diet) and were then placed on a HF/HS + HSG4112 
(100mg/kg) at the start of fourth week for another 3 weeks of feeding. The 
end of sixth week of feeding, the experiment was terminated. (B) Changes 
in weight (grams) were determined between the weight of the mice at week 
1 and week 3, and at week 3 and 6. Changes in fat mass (C) and muscle 
mass (D) in the mouse groups fed HF/HS for three weeks, followed by 
HF/HS + HSG4112 diet for another 3 weeks were assessed. Data was 
quantified as percentage of final fat/muscle mass (grams) over total body 
weight (grams) x 100, at the start of the experiment (week 0), as well as the 
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end of week 3 and 6. (E) Food consumption was measured per mouse 
cage with every food change over the course of the six week diet study for 
male and female, WT and PON2-def mice. The percent of food consumed 
was determined as the amount of food consumed over the total amount of 
food originally provided per food container x 100. The data is represented 
as Mean ± SEM and statistically significant data is noted as *p<0.05, 
**p<0.01, and ****p<0.0001. 
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Figure 27: HSG4112 Protection Against Diet-Induced Obesity in 
Hyperlipidemic Mice. (A) LDLR-KO mice were utilized to investigate the 
role of HSG4112 against diet-induced obesity. Mice were fed 4 different 
diets for 3 weeks: Chow ±  HSG4112 or Western Diet (WD) ± HSG4112. 
Dosing of HSG4112 was at 100mg/kg. Both male and female mice, 
between 8-12 weeks of age, with 5 mice per group. The mice were 
weighed prior to the start of the experiment. At the end of third week of 
feeding, the experiment was terminated. (B) Changes in weight (grams) 
were determined between the weight of the mice before the start of the 
experiment and final weights prior to termination. (C) Fat mass changes 
were assessed and quantified as percentage of final fat mass (grams) over 
total body weight (grams) x 100. (D) Muscle (lean) mass changes were 
assessed and quantified as percentage of final muscle mass (g) over total 
body weight (grams) x 100. Arylesterase and lactonase activities were 
determined in plasma (terminal plasma collection) (E) and livers (F). 1 
unit=µmole of dihydrocumarin (for lactonase) or phenyl acetate (for 
arylesterase) hydrolyzed per minute. The data is represented as Mean ± 
SEM and statistically significant data is noted as *p<0.05,**p<0.01, 
***p<0.001, ****p<0.0001. 
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Supplementary Figure 6A 
 
                   
 
 
Supplementary Figure 6B 
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Supplementary Figure 6C 
 
                                 
 
 
 
 
 
 
 
Supplementary Figure 6: PON2 induction by HSG4112 in a Diet-
Induced Obesity Model. WT, C57BL/6J mice were fed normal, chow diet 
or an obesifying diet with and without HSG4112 (100mg/kg) for 6 weeks. In 
the livers, protein expression was assessed via western blot (A) and 
quantified as fold change (B). Also, PON2 gene expression was 
determined (C). [Data from Glaceum, Inc.; data unpublished] 
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Table 4: Plasma lipid panel and glucose levels of WT/PON2-def mice 
fed a HF/HS ± HSG4112 Diet for 3 weeks. 
 
WT/PON2-def: Male 
Group n TG TC HDL UC Glucose 
WT- WD 4 40.25 ± 1.5 149.5 ± 29.6 119 ± 18.2 22.5 ± 5.4 189.7 ± 3.5 
WT-  
WD + HSG4112 
4 103.75 ± 32.9 147.75 ± 42.8 108 ± 28.7 28 ± 4.8 136 ± 20.7 
p value  0.008 0.95 0.54 0.18 0.03 
PON2-def- WD 6 59 ± 13.4 118.8 ± 12.9 98.2 ± 12.7 17.3 ± 2.8 126.7 ± 11.6 
PON2-def-  
WD + HSG4112 
6 70.3 ± 22.3 125.3 ± 7.3 102.2 ± 4.7 19.8 ± 2.2 106.5 ± 18.1 
p value  0.31 0.31 0.49 0.12 0.04 
 
WT/PON2-def: Female 
Group n TG TC HDL UC Glucose 
WT- WD 5 32 ± 12.1 101.2 ± 8.6 81.4 ± 5.1 11.4 ± 1.1 131.8 ± 24.1 
WT- WD + HSG4112 5 35.8 ± 12.6 98 ± 13.6 71.6 ± 7.8 15.6 ± 5.4 112.2 ± 15.7 
p value  0.64 0.67 0.04 0.13 0.17 
PON2-def- WD 5 39.4 ± 7.8 106.2 ± 5.8 87.2 ± 3.8 13 ± 1.6 115.6 ± 17.8 
PON2-def- WD + HSG4112 5 26.4 ± 5.6 109.8 ± 17.1 85.4 ± 17.0 15.8 ± 3.3 114.2 ± 25.9 
p value  0.02 0.67 0.82 0.12 0.92 
Values are represented as mean ± standard deviation. Units are in mg/dl. 
Abbreviations: TG: triglycerides, TC: total cholesterol, HDL: high density lipoprotein, and 
UC: unesterified cholesterol.  
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Table 5: Plasma lipid panel and glucose levels of LDLR-KO mice fed a 
Chow ± HSG4112 or WD ± HSG4112 for 3 weeks.  
 
LDLR-KO: Male 
Group n TG TC  HDL UC Glucose 
Chow 4 40.7 ± 2.1 274.5 ± 24.2 112 ± 9.7 64.5 ± 13.7 210.5 ± 98.7 
Chow + HSG4112 5 112.4 ± 14.5 278 ± 22.4 102.4 ± 14.9 71.6 ± 5.2 113.4 ± 45.5 
p value  0.0002 0.83 0.30 0.32 0.09 
WD 5 105 ± 50.2 1118 ± 127.5 90.2 ± 17.5 314.4 ± 42.6 196.4 ± 55.1 
WD + HSG4112 5 122.8 ± 24.5 914.8 ± 124.2 87.8 ± 22.1 272.4 ± 32.8 147.8 ± 49.5 
p value  0.5 0.03 0.85 0.12 0.18 
 
LDLR-KO: Female 
Group n TG TC HDL UC Glucose 
Chow 5 50 ± 12.3 261.6 ± 13.2 87 ± 15.7 62.8 ± 4.6 196 ± 28.5 
Chow + HSG4112 5 116 ± 10.4 311.2 ± 53.3 78.6 ± 17.3 88.4 ± 25.3 98.6 ± 19.1 
p value 
 
6.01E-05 0.08 0.45 0.06 0.0002 
WD 5 74.4 ± 41.2 1030.4 ± 133.3 95.4 ± 11.0 290.8 ± 37.8 188.25 ± 34.4 
WD + HSG4112 5 117.2 ± 30.3 932 ± 106.2 77.6 ± 11.3 272.8 ± 36.9 142.4 ± 29.2 
p value 
 
0.09 0.23 0.04 0.47 0.06 
Values are represented as mean ± standard deviation. Units are in mg/dl. 
Abbreviations: TG: triglycerides, TC: total cholesterol, HDL: high density lipoprotein, and 
UC: unesterified cholesterol.  
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Chapter 6: Conclusion and Future Direction 
Abbreviations:  
CVD Cardiovascular Disease 
CHD Coronary Heart Disease 
CAD Coronary Artery Disease 
PON Paraoxonase  
3OC12-HSL N-(3-oxododecanoyl)-1-homoserine lactone 
WT Wild-type 
PON2-def PON2-deficient  
LDLR-KO Low density lipoprotein receptor knock-out 
WD Western diet 
HF/HS High fat/high sucrose 
ROS Reactive oxygen species 
RISK Reperfusion injury salvage kinase 
HETE 5-Hydroxyeicosatetraenoic acid 
POVPC 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine 
PGPC 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine 
AA  Arachidonic acid 
LA Linoleic acid 
cPLA2 Cytoplasmic phospholipase A2 
5-HETEL (±) 5-hydroxy-6 E,8 Z,11 Z, 14 Z-eicosatetranenoic acid 1,5-lactone. 
 
 PON2 has a plethora of anti-oxidant and anti-inflammatory properties that affect 
a variety of disease models, including cancer, cardiovascular disease (atherosclerosis), 
and obesity.4, 6 The protective capacity of PON2 against CVD was thoroughly explored 
in this thesis, specifically expanding our novel understanding of PON2’s protection 
against myocardial IRI and its potentially casual role in mediating the protective effects 
of a novel therapeutic, HSG4112, against one of the leading CVD risk factors, diet-
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induced obesity. Many of the antioxidant properties of PON2 converge on the 
mitochondria, a fundamental organelle affected by myocardial IRI, leading me to 
hypothesize that PON2 has a protective capacity against myocardial IRI by modulating 
mitochondrial dysfunction, oxidative stress, and lipid peroxidation.  
My recent publication (Chapter 2) demonstrated the cardioprotective role that 
PON2 possesses against myocardial IRI in cardiomyocytes, specifically by mitigating 
mitochondrial dysfunction (preserving mitochondrial membrane potential and calcium 
retention capacity) and oxidative stress (reduction of ROS production), and reducing cell 
apoptosis/necrosis.50 Additionally, the RISK signaling pathway (PI3K, Akt, GSK-3β) was 
determined to be a potential mechanism by which PON2 modulates myocardial IRI. 
Given the pivotal role that PON2 plays within the mitochondria during myocardial IRI, 
particularly in mitigating ROS production, I explored PON2’s capacity to modulate 
mitochondrial lipotoxicity, both in membrane phospholipids and as esterified and 
unesterified eicosanoids and prostanoids, the oxidation products of LA and AA (Chapter 
3). I found that PON2 deficiency leads to an increase in both mitochondrial phospholipid 
oxidation (POVPC and PGPC) and eicosanoid production and a decrease in prostanoid 
production post-myocardial IRI; all of which is rescued, at least in part, by PON2 
overexpression. Additionally, the ability of PON2 to modulate mitochondrial lipid 
peroxidation of AA and downstream eicosanoid and prostanoid production, points to 
potentially novel substrates/mechanism of action for PON2. The increased unesterified 
eicosanoid production, although partly explained by the increased expression of cPLA2, 
is still far from being resolved. It still remains to be determined whether PON2 
modulates lipoxygenase enzymatic function to produce the increase of eicosanoids or 
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whether PON2 is interacting directly with the unesterified AA, potentially revealing novel 
substrates for PON2. In fact, the potential interaction of PON2 with AA products is not 
new. It has been shown in vitro that PON2 metabolizes 5-HETEL, which is a product of 
both enzymatic and nonenzymatic oxidation of AA.100 Therefore, evaluating PON2 
binding affinity to various eicosanoids, particularly 12-HETE and 15-HETE, is of great 
importance. Also, the decrease in mitochondrial prostanoid production in PON2-def 
mice further suggests the potential interaction of PON2 with cyclooxygenase (COX1 
and 2), another avenue crucial to investigate.   
 An interesting observation made during these studies was the susceptibility of 
PON2-def mice to small, yet significant, injuries under baseline, untreated conditions. 
For example, the mitochondria of PON2-def mice had reduced calcium retention 
capacity (Chapter 2) and increased lipid peroxidation in the form of HETE and POVPC 
production (Chapter 3). Although these injuries do not culminate in any overt pathogenic 
phenotype, their presence indicates that PON2 deficiency primes the tissue for 
increased injury when a stressor is introduced, such as myocardial IR in these studies.  
The PON2-deficient mouse model utilized in the various experiments throughout 
this thesis is a global “knock-out” of PON2, creating a limitation in understanding the 
role of PON2 exclusively in the heart and more specifically within cardiomyocytes, the 
key cellular subtype affected by myocardial IRI.44 Therefore, generating cardiac-specific 
PON2 knock-out (KO) mouse models allows for the investigation of the role that PON2 
plays specifically in the cardiomyocytes, while minimizing any off-target or 
compensatory responses that can arise from the global PON2 “knock-out” model. 
Consequently, I generated two novel cardiomyocyte-specific, PON2 KO mouse models 
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using a CRISPR/Cas9 and FLP-Cre Recombinase system (Chapter 3). Although I have 
not been able to use these mice due to time constraints, there are two fundamental 
experiments that I would like to perform using them. The first would be characterizing 
the mice under baseline, untreated conditions. This would include isolating different 
tissue types (liver, spleen, lungs, etc.) as well isolating the cardiomyocytes from both 
the control and cardiomyocyte-specific PON2-KO mice and determining the expression 
of PON2, enzymatic capacity (lactonase and arylesterase activity), oxidative stress 
(ROS production), and mitochondrial bioenergetics (oxygen consumption rate). 
Nevertheless, these novel transgenic mice strains are fundamental in enabling a robust 
and effective model for the investigation of PON2 in myocardial IR injury, as well as 
other cardiovascular disease paradigms. The extensive data that I have generated 
(Chapters 2 and 3) during the course of my studies greatly supports the hypothesis that 
PON2 is protective against myocardial IRI, particularly in the cardiomyocytes, by 
modulating mitochondrial dysfunction, oxidative stress, and lipid peroxidation.  
Accordingly, my second experiment would be subjecting the cardiomyocyte-specific 
PON2-KO mice to myocardial IRI. I hypothesize that PON2 deficiency only in 
cardiomyocytes will be sufficient to lead to an exasperated myocardial IRI phenotype. 
This would include the induction of a larger infarct size, greater mitochondrial 
dysfunction (reduced mitochondrial membrane potential and calcium retention capacity) 
and oxidative stress (increase ROS production), and increased mitochondrial lipid 
peroxidation (increased eicosanoid formation and phospholipid oxidation).   
 I was very fortunate to have the opportunity to investigate the role of a novel 
compound, HSG4112, against diet-induced obesity and the potential role that PON2 
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plays in modulating its protective effects (Chapter 5). Diet-induced obesity is one the 
lead risk factors leading to CVD, particularly CHD. Therefore, finding therapeutic targets 
that can mitigate this destructive risk factor is of critical importance.  HSG4112 
increased PON1 and PON3 expression and enhanced lactonase and arylesterase 
activity in the plasma and livers of WT, PON1-KO, and PON2-def mice under baseline, 
chow fed conditions, suggesting that the drug’s protective effects are, at least in part, 
through the Paraoxonase gene family. As noted earlier, Glaceum found that PON2 was 
induced with HSG4112 in diet-induced obesity studies. Therefore, I performed two diet-
induced obesity studies using our PON2-def mouse line to evaluate the potentially 
casual role that PON2 plays in HSG4112 protection. Although there was a significant 
decrease in body weight in both male and female, WT and PON2-def mice, the female, 
PON2-def mice had a reduced change in body weight, no fat mass loss, no gain of 
muscle mass, no decrease in plasma glucose levels, or enhanced (plasma) lactonase 
activity when compared to the WT controls. Therefore, based on these studies, PON2 
deficiency, in females, significantly reduces, although not completely, the protective 
capacity of HSG4112. This suggests, that some of HSG4112’s protective effects are 
independent of PON2. Consequently, I wanted to evaluate the protective capacity of 
HSG4112 against another model of diet-induced obesity, one that involves 
hyperlipidemia. HSG4112 significantly reduced body weight and fat mass, while 
increasing muscle mass in hyperlipidemic, LDLR-KO mice (male and female) fed a 
western diet with HSG4112. It is worth noting that these protective effects were not 
observed in the LDLR-KO, chow fed group with the drug, suggesting that an external 
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stressor, in this case obesifying diet, is required in spite of being predisposed to 
hyperlipidemia.  
 Lastly, another important avenue to explore is the potential of HSG4112 to 
modulate mitochondrial lipid peroxidation. According to data from Glaceum, a key 
mechanism of action of HSG4112’s protection in diet-induced obesity is the reduction of 
mitochondrial dysfunction, through the reduction of ROS generation and increase in 
ATP production (data unpublished). This data, coupled with the capacity of HSG4112 to 
induce PON2 expression, further supports the hypothesis that PON2 modulates the 
protective properties of HSG4112. Therefore, given my observations on the protective 
role that PON2 plays in reducing mitochondrial dysfunction and oxidative as well 
reducing mitochondrial lipid peroxidation, I hypothesize that part of HSG4112’s 
protective properties include it’s ability to reduce mitochondrial lipid peroxidation. As a 
result, HSG4112 has the potential to be utilized as a therapeutic agent against 
myocardial IRI. Two experiments can be performed to test my hypothesis. The first 
would be a quick cell culture experiment where I would subject H9c2 cells to my 
established in vitro HRI protocol with and without HSG4112 treatment. I would then 
isolate mitochondria from these cells and determine the mitochondrial lipid peroxidation 
using our existing mass spectrometry method. The second experiment would involve 
feeding my newly generated cardiomyocyte-specific KO mice (and controls) with 
HSG4112 for 3 weeks, after which I would subject the mice to myocardial IRI. 
Mitochondria will then be isolated from these mice and mitochondrial lipid peroxidation 
will be determined via mass spectrometry. I hypothesize that HSG4112 treatment will 
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protect against myocardial IRI by reducing cell death (decreased infarct size) and 
protecting against mitochondrial dysfunction and lipid peroxidation.  
 My dissertation work has explored the protective capacity of PON2 against CVD, 
specifically expanding our understanding of its cardioprotective role against acute 
myocardial IRI. This protective capacity is largely rooted in PON2’s modulation of 
mitochondrial dysfunction and oxidative stress, particularly lipid lipotoxicity. In addition, I 
investigated the protective role of HSG4112, a novel drug that protects against diet-
induced obesity, and the potentially causal role that PON2 plays as its mode of action. 
In conclusion, these studies help determine possible physiological substrates and 
molecular mechanisms of PON2, which remain largely unknown, as well as targets for 
therapeutic intervention against myocardial IRI and diet-induced obesity. 
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